UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-KSB





(X)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
     For the fiscal year ended March 31, 2004
                               --------------

( )TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934
                 For the transition period from              to
                                                ------------    --------------

Commission File Number: 000-49620

                                  Cobalis Corp.
                                  -------------
        (Exact name of small business issuer as specified in its charter)

Nevada                                                               91-1868007
------                                                               ----------
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)


                   2445 McCabe Way, Suite 150, Irvine, California 92614
--------------------------------------------------------------------------------
                         (Address of principal executive offices)

                                 (949) 757-0001
                                 --------------
                           (Issuer's Telephone Number)

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practical date. As of June 16, 2004 there were
24,368,983 shares of the issuer's $.001 par value common stock issued and
outstanding.*

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.   (X) Yes   ( ) No

Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. ( )

State issuer's revenues for its most recent fiscal year: $4,708.

State the aggregate market value of the voting and non-voting common equity held
by non-affiliates computed by reference to the price at which the common equity
was sold, or the average bid and asked price of such common equity, as of a
specified date within the past 60 days. (See definition of affiliate in Rule
12b-2 of the Exchange Act.) As of June 18, 2004, approximately $8,988,403.50.

Documents incorporated by reference. There are no annual reports to security
holders, proxy information statements, or any prospectus filed pursuant to Rule
424 of the Securities Act of 1933 incorporated herein by reference.

Transitional Small Business Disclosure format (check one):  ( ) Yes    (X)  No


                                       1
<PAGE>

*Represents stock issued and outstanding in Cobalis Corp., the reporting issuer.
The attached financial statements reflect a total of 24,119,708 shares issued
and outstanding as of March 31, 2004. That will be the number of shares issued
and outstanding when the Cobalis Corp. formerly known as BioGentech Corp. (the
reporting issuer) stock is issued to the BioGentec Incorporated (the
wholly-owned subsidiary of reporting issuer) ("BioGentec") shareholders in
exchange for their BioGentec Incorporated stock. Included therein are 3,000,000
shares of Cobalis's common stock that have been issued as collateral for a
transaction that did not occur, and these shares were cancelled as of July 9,
2004.

                                     PART I

ITEM 1. DESCRIPTION OF BUSINESS.
--------------------------------

We changed our corporate name to Cobalis Corp. with the filing of a Certificate
of Amendment to our corporate articles in Nevada on July 6, 2004. We are a
development stage company dedicated to the development and commercialization of
medical products, focused primarily in the fields of allergic disease.

The indications include:

o    Seasonal allergic rhinitis (seasonal allergies or outdoor allergies)
o    Perennial allergic rhinitis (year-round or indoor allergies)
o    Pediatric dosing for seasonal allergic rhinitis
o    Allergic asthma
o    Food allergies (including peanut)
o    IgE-mediated skin disorders (dermatitis, chronic urticaria,
     eczema, psoriasis)
o    Allergic and migraine headache

We anticipate that our initial patented product, PreHistin (TM), will create a
unique niche within the allergy relief category. We hope to conduct operations
by selling our initial product, PreHistin (TM), which we believe can prevent
allergy symptoms by mitigating histamines from being over-produced. We hope to
obtain the appropriate regulatory approvals and market our product in the United
States and abroad, though there is no guarantee that we will be able to do so.

OUR SUBSIDIARY. BioGentec, which has become our wholly-owned subsidiary as
described above, was incorporated in Nevada on November 21, 2000. BioGentec
anticipates that its initial patented product, PreHistin (TM), (formerly
Allertin), will create a unique niche within the allergy relief category. In
November 2000, BioGentec acquired certain intangible assets and sample
inventories from Gene Pharmaceuticals, LLC (formerly Allergy Limited, LLC). Gene
Pharmaceuticals, LLC Limited sponsored the clinical research for PreHistin
(TM)'s formula from 1989 through 2000 and secured the first patent, in 1992 and
BioGentec secured the second in 2001. References herein to our subsidiary may be
construed as our activities and operations, in that all of our activities are
conducted through this subsidiary.

BIOGENTEC'S PRODUCT. BioGentec believes that its initial product, PreHistin
(TM), is chemically distinct from most allergy medications currently on the
market, as it works to prevent allergy symptoms by mitigating histamines from
being over-produced, as opposed to conventional of antihistamine products that
are reacting to the overproduction. Essentially a "pre-histamine", BioGentec
believes that PreHistin (TM) will also be differentiated from current allergy
medications as it lacks the sedating and other side effect that are common to
current medications. PreHistin (TM) is a preventative system for seasonal and
year round allergies, both outdoor (i.e., pollen) and indoor (i.e., dust, pet
dander, mold), triggered by the most common allergens. This 21-day system of
flavored lozenges was demonstrated in clinical studies to have a persistence of
effect lasting months.

BioGentec believes that PreHistin (TM)'s effectiveness is due to modulating the
production of immunoglobulin E (IgE) to prevent the immune system from
overproducing histamines in reaction to the presence of allergens. By mitigating
this process, BioGentec expects that the symptoms associated with indoor and
outdoor allergies can be prevented from occurring. Effectively, the terminology
for this product is "prehistamine". BioGentec believes that the products
currently addressing allergy relief are virtually all histamine reactive and
have varying side effects, which are a source of frustration for allergy
sufferers. BioGentec believes that PreHistin (TM), a patented and unique
cobalamin complex formula, has preventative effectiveness, with no known side
effects, has no negative drug interactions and no upper dosage limit. BioGentec
believes that PreHistin (TM) will be cost competitive relative to the long
lasting relief and benefits desired by the vast majority of allergy sufferers.


                                       2
<PAGE>

PreHistin (TM) is an immunomodulation ("anti-IgE") product. Immunoglobulin E
(IgE) is an antibody that mediates allergic diseases such as allergic rhinitis,
allergic asthma and atopic dermatitis. In the 1990's, research was completed
relative to IgE and allergies/asthma. Using this past research to develop
PreHistin (TM), we believe this product will offer the sufferers of allergic
rhinitis (airborne allergies) the effectiveness that comes from IgE reduction
and histamine production mitigation using a sublingual lozenge, i.e., one that
is placed under the tongue to deliver the medication into the body. We believe
that behind PreHistin (TM), there is over 25 years of scientific research and
testing completed by leading allergists and immunologists. The double blind,
placebo-controlled studies required by the FDA were completed and validate the
safety and efficacy of this new approach. The protocols for Phase III trials are
being finalized, which will lead to execution of the trials and application for
FDA over-the-counter medication approval. We anticipate that the planned cost of
our product to the consumer will well within the over the counter allergy
medication category's acceptable range.

Domestically, PreHistin (TM), our allergy treatment formula, is in Phase III
clinical trials as of March 2004.

This phase is generally considered the last step in clinical drug development
before submission of a New Drug Application (NDA) requesting marketing approval
from the FDA and similar regulatory agencies outside the USA.

We have also submitted an Investigational New Drug application (IND) to the FDA
which has been assigned the IND number 68,994. The FDA has reviewed our two
Phase 3 study protocols and indicated that we are "safe to proceed" with the
trials. Our regulatory team and our clinical research organization (CRO),
ClinDatrix of Irvine, CA are working with the Division of Pulmonary and Allergy
Drug Products at the FDA to finalize the Phase 3 study protocols.

Additionally, we plan to conduct pharmacokinetics and animal studies on the
final clinical formulation.

Although we cannot predict with any certainty if or when the studies will be
completed (a situation that could negatively impact our ability to earn
revenues), we expect that all of the above studies will be essentially completed
by the end of 2004. The FDA has the power and authority to halt our clinical
trials, in particular if they determine that the patients' safety is at an
unjustifiably high risk.

Human clinical trials are very expensive and difficult to design and implement,
in part because they are subject to rigorous regulatory requirements. The
clinical trial process is also time-consuming. We estimate that clinical trials
of our product candidates will take at least several months to complete. Failure
of the trials can occur as a result of cost overruns or other financial
considerations. Furthermore, failure can occur at any stage of the trials, and
we could encounter problems that cause us to abandon or repeat clinical trials.

Internationally, we are working through the various regulatory bodies in
targeted countries to determine if we will be seeking approval of PreHistin (TM)
as an over-the-counter ("OTC") or prescription medication, or approval of
Prevahist (TM), a revised formula to be a nutritional supplement.

INVESTIGATIONAL PRODUCT. Cyanocobalamin is a synthetic form of vitamin B12 and
one of a class of molecules known as cobalamins. Cobalamins are believed to be
the only molecules in the human body that contain cobalt. Each active lozenge
will contain 3300 ig (3.3 mg) of pharmaceutical grade cyanaocbalamin. This
Cyanocobalamin, USP is described in the USP, FCC and Pharmacopoeia of Europe. It
is shipped from: DSM Nutritional Products, Inc., 45 Waterview Blvd., Parsippany,
NJ 07054-1298 USA. See: http://www.nutraaccess.com/productDoc/pds/pds_0429155.
pdf for product data sheet. Cyanocobalamin, USP is an FDA approved drug.
Cyanocobalamin has a long shelf life, of about 60 months.

With respect to cobalamin, we believe that "based on a review of data involving
high dose intakes, that there appear to be essentially no risks of adverse
effects to the general population even at the current ninety-fifth percentile of
intake (approximately 37 ig /day) (IOM/NAS 1998)". Christine J. Lewis, Ph.D.,
Director, Center for Food Safety and Applied Nutrition, FDA.
(www.cfsan.fda.gov/~dms/ds-ltr12.html).


                                       3
<PAGE>

OUR SUPPLIERS. We believe that the active ingredients needed to produce our
proposed product are readily available through several manufacturers,
domestically and internationally, including major pharmaceutical corporations.
Roche Labs is a primary source for us and we will expect to have a variety of
suppliers as we enter various international markets and, should we be able to
begin commercial production of our product, we anticipate we will be able to
determine the most efficient and cost effective manufacturing source. We do not
have a written agreement with Roche Labs, however, we believe we would be able
to obtain the ingredients needed to produce our product from other sources
should Roche Labs cease to be a source of ingredients for us.

OUR CHANNELS OF DISTRIBUTION. We do not currently produce or distribute our
products for sale; however, once we are able to commence commercial production,
we plan to outsource the manufacturing and distribution operations to proven
manufacturers and distributors in these areas. We anticipate using a combination
of pharmaceutical wholesalers-distributors as well as selling directly to
retailers, particularly those with internal distribution systems. From a sales
perspective, we hope to utilize key sales leaders and to engage a broker network
to minimize overhead and gain nationwide coverage from proven sales
professionals. We also anticipate that our product will be sold by independent
pharmacies through the pharmaceutical wholesalers' networks. We anticipate that
internationally, each market and country will be a unique set of logistics,
depending on whether that country classifies the product as a supplement or a
medicine, whether we are entering the market directly or using a partner (and
the extent of the partnership arrangement) and the distinct dynamics of the
marketplace.

MANUFACTURING. BioGentec is currently attempting to identify a manufacturer to
produce the Phase III trial medications as well as the first runs of the retail
version of the product. The domestic manufacturer selected must be FDA approved
and able to accommodate the anticipated demand, once the information is
broadcast publicly. In addition, BioGentec is considering various manufacturers
around the world to accommodate demand and/or meet critical regulatory
requirements to distribute this product within a given country.

MATERIAL CONTRACTS. In 2000, BioGentec purchased the patent underlying our
principal product (formerly known as "Immun-Eeze"), along with pending
international patent applications, and certain other tangible assets and related
trademarks, and copyrights from Gene Pharmaceuticals, LLC, for $150,000 plus
royalties tied to future sales which should not be less than a minimum royalty
amount of $3,780,000. In December 2002, the parties agreed to amend the original
agreement to settle the unpaid minimum royalty through issuance of 2,000,000
shares of BioGentec's common stock, plus royalties on future sales of products.
In March 2004, we tentatively agreed to further amend the original underlying
agreement and the terms of the royalty provision in the underlying agreement,
although the specific terms have not yet been finalized. We are currently
negotiating the amendments to the original agreement.

OUR INTELLECTUAL PROPERTY. Our success depends in part upon our ability to
preserve our current intellectual property rights and those we may acquire in
the future. Our success will also depend in part on our ability to operate
without infringing the proprietary rights of other parties. However, we may rely
on certain proprietary technologies, trade secrets, and know-how that are not
patentable or protectable by other means.

PATENTS. BioGentec's patents cover the delivery and use of cobalamin for
seasonal and year-round allergies (allergic rhinitis) and asthma. The patents
are:

o    United States Patent #6,255,294 "Cyanocobalamin Treatment in Allergic
     Disease"
o    United States Patent #5,135,918 "Method for Reducing Reagenic Antibody
     Levels (IgE)"
o    Japan Patent Pending # P2002-533399A (Same as U.S. #6,255,294)
o    Mexico Patent Pending # 2001-006297 (Same as U.S. #6,255,294)
o    Australia Patent # 771728  (Same as U.S. #6,255,294)
o    Pending patents in European Union, and Canada. (Same as U.S. #6,255,294)

Because we believe that BioGentec's patents are the only patents to date related
to the subject, the claims are broad.

Although we believe that the subject matter covered by our patents and pending
patent applications has been developed independently and does not infringe on
the patents of others, there can be no assurance that the technology does not
and will not infringe on the patents of others. In the event of infringement, we
could, under certain circumstances, be required to modify our infringing product
or process or obtain a license. There can be no assurance that we would be able
to do either of those things in a timely manner or at all, and failure to do so
could harm us and our business. In addition, there can be no assurance that we
will have the financial or other resources necessary to enforce a patent
infringement or proprietary rights violation action or to defend itself against
such actions brought by others. If any of the products or processes we have
developed infringe upon the patent or proprietary rights of others, we could,
under certain circumstances, be enjoined or become liable for damages, which
would harm our business.


                                       4
<PAGE>

TRADEMARKS. We currently use or propose to use the trademarks or trade names
Biogentec, BioGentech, Cobalis, PreHistin (TM), Pre-Histamine and Prevahist (TM)
to distinguish our brands from others. We hope to obtain registration for our
trademarks for our proposed products in the future and in March 2004, we
submitted registration applications for the marks Cobalis and PreHistin (TM).
Obtaining a trademark will grant us the exclusive right to use or license such
trademarks and will substantially assist us in the protection of our brand name
and image. Once obtained, we will regard the license to use any trademarks we
acquire and any other proprietary rights in and to the trademarks as valuable
assets in the marketing of our products and we will actively seek to protect
them against infringement. If we establish our brand, we may also create an
enforcement program to control the sale of counterfeit products in the United
States and in major markets abroad. Any trade names and trademarks developed can
be helpful in garnering broad market awareness of our products and will be
significant in marketing our products. Therefore, we propose to adopt a policy
of vigorous defense of our trademarks against infringement under the laws of the
United States and other countries.

In November 2003, a trademark infringement and unfair competition suit filed in
November 2003 by Biogen Idec MA Inc. ("Biogen") against us in the U.S. District
Court for the District of Massachusetts, file # C.A. 03-123-5 PBS. A default
judgment was entered against us on February 9, 2004 and subsequently on or about
March 22, 2004, we and Biogen agreed to settle the dispute. On April 14, 2004,
Biogen undertook to file a motion for stay of consideration of its motion for
entry of default judgment and has prepared a consent judgment to be filed with
the court. Pursuant to the consent judgment, we will be enjoined from using
"Biogentec" or "Biogentech" or any phonetic equivalent, and we will consent to
change our corporate name to Cobalis Corp. as soon as practicable and to
discontinue all uses of the trade name and trademarks and domain names
containing "Biogentech," or "Biogentec" and transfer the rights to any domain
names we may own containing "Biogentech" or "Biogentec" to Biogen as soon as
practicable. We estimate that the costs of transferring the domain name
registrations and changing the corporate name will be minimal, and we will
undertake to change our corporate name by means of a shareholder vote to be
conducted as soon as practicable. As of April 14, 2004 we are discussing with
Biogen the time within which we will have to effectuate the changes noted above.
We have executed a settlement agreement with Biogen, pursuant to which we will
undertake to comply with the terms of the consent judgment. As of July 6, 2004,
we had filed a Certificate of Amendment to our corporate articles in Nevada to
effect our name change to Cobalis Corp.

In 2004, the Company engaged Gemini Partners to perform an independent
appraisal on its patents. On April, 30, 2004, Gemini Partners completed an
Intellectual property valuation analysis on the Company's patent # 5.135.918
and # 6.255.294 and concluded that the cost of purchasing or producing a
substitute asset with the same utility as the Company's patents can be
reasonably estimated at $6,500,000.

WEBSITES. Cobalis Corp. has developed a corporate site, www.cobalis.com,
targeted to the investor, corporate and health professional community;
describing the science behind our flagship allergy prevention product,
PreHistin. In addition, the site contains information of value to the consumer,
the allergy sufferer. The site will be updated continuously to include the
latest news and information about PreHistin, as well as our upcoming Phase III
clinical trials program.

The Company is also planning to create a comprehensive website primarily
targeted to consumers, which will include interactive features for allergy
sufferers as well as detailed updates as PreHistin comes closer to being made
available to the consumer market.

Both sites will be translated into multiple languages to engage the
international health professional, reflect local regulations and consumer
communities.


                                       5
<PAGE>


TARGET MARKET. Cobalis' PreHistin product will be targeted to those individuals
who suffer from allergic diseases, including seasonal allergies, perennial
allergies and other allergic diseases and conditions. Cobalis believes that
allergy sufferers are constantly seeking relief from their symptoms and a "new
approach" to address those symptoms if their current approach is not working or
if they would prefer an approach that is geared more towards prevention of
allergy symptoms than to treating these symptoms with powerful and often
uncomfortable antihistamines. To maximize the revenue growth, Cobalis is
planning to execute a fully integrated marketing campaign including broadcast
and print advertising, direct mail and an aggressive public relations campaign,
educating consumers, health professionals, corporate human resources personnel
and caregivers on the product and driving retail sales of PreHistin (TM) once
our Phase III Clinical Trials are complete, and we receive anticipated approval
from the US FDA to market PreHistin with a claim that PreHistin will prevent the
onset of allergy symptoms.

In addition to the initial formula of PreHistin, Cobalis plans to test, and gain
approval for, alternative delivery mechanisms for the same drug. The mechanisms
that will be tested include liposomal sprays, liquid drops, quick dissolve
tablets and quick dissolve strips, among others, which we hope will result in 3
to 7 products in the PreHistin line. Cobalis is also developing clinical trial
protocols to gain supplemental indications for this drug, such as sinusitis,
allergic asthma and pediatric cases of each, and, upon FDA approval, as a
treatment for allergic rhinitis. Cobalis is planning to launch one to two new
products per year, either from its development pipeline or through acquisition
or licensing of late stage development products.

Cobalis anticipates execution of a cooperative marketing/product licensing
agreement with a major international pharmaceutical manufacturer/distributor, to
augment Cobalis' resources to complete the Phase III program, and to bring the
product to market quickly and effectively. In addition, Cobalis intends to
launch marketing campaigns directly to retail pharmacy chains and work
collaboratively with the retailers via co-marketing, co-branding and in-store
promotions that will build brand awareness and assist in educating the consumer.
Further, Cobalis intends to create and implement significant programs into the
corporate health and wellness community to bring the benefits of PreHistin to
the workplace, where today productivity suffers from work days lost to allergy
suffering. Cobalis believes that its product works very differently (in advance
of allergy symptoms to prevent their onset) from what consumers have learned to
expect from any other products (which only treat allergy symptoms) in the
category, making it critical that consumer education be woven in to all aspects
of the marketing program.

OUR MARKETING STRATEGY. We believe that PreHistin is in an ideal position to
capture market share with a unique product focused on preventing the symptoms of
allergic rhinitis. We believe that this breakthrough technology (mediation of
IgE synthesis) and unique approach to allergy symptoms reduction makes the
upcoming PreHistin launch newsworthy, and will help us to leverage a
cost-effective publicity campaign.

From a consumer advertising perspective, we are planning, domestically, to
execute a targeted, pilot market campaign once we receive approval from the US
FDA to commence marketing of PreHistin, ensuring the product is in market prior
to the prime ragweed hay fever season. This program is scheduled to be a limited
release in six markets, strategically chosen based on four criteria:

       o one of the top 25 allergy suffering markets
       o efficiency and cost-effectiveness of media
       o public relations access to high quality media
       o geographic dispersion

We hope that this staged launch will provide the opportunity to drive revenue
and gain knowledge through execution. This in-market experience will lead to
fine-tuning the message, refining the communications formats and evaluating the
pricing elasticity, thereby maximizing the effectiveness of a national launch to
follow. Conclusion of a major licensing agreement with a leading pharmaceutical
company would greatly accelerate our ability to come to market on a national
basis more quickly.


                                       6
<PAGE>

We anticipate completion of the Phase III Clinical Trials during 2005, with a
pilot market roll out in early 2006, providing enough time to implement a
widespread consumer education campaign prior to the allergy season. Once the
pilot market launches are completed, we expect that we will fine tune a media
and publicity plan, as well as the price point and message, to hopefully allow
us to launch nationwide and internationally.

THE INTERNATIONAL MARKETPLACE. Internationally, we are working to gain approval
for a supplement version of our allergy prevention formula, Prevahist (TM), in
Canada, capitalizing on the new regulations that we believe will allow
supplements to make strong marketing claims, provided they are supported with
scientific evidence. We believe that Cobalis' formula, as explained above, has a
sufficient amount of science to validate its effectiveness, so we hope to gain
approval in the Canadian market. We are exploring similar opportunities in
several countries throughout the world as we believe that there is much greater
acceptance of supplements internationally. As the markets for this opportunity
are uncovered, we plan to aggressively market and distribute Prevahist (TM), by
using in-house resources, creating a joint venture and/or authorizing a product
licensing, marketing and distribution agreement. Currently, we have no such
agreements in place.

We are considering distribution of PreHistin in various countries throughout the
world. We believe that early signs show the potential ability to drive revenue
from other countries to be strong, while growing dramatically in the event that
the United States FDA approves the drug as a treatment for allergies.
Internationally, Coablis is in discussions with companies in Japan, Asia, Mexico
and the EU, to operate as partners in working PreHistin through their regulatory
processes and launching it to a broad network of retailers and physicians.
However, Cobalis has not yet entered into written agreements with such parties.
Cobalis is evaluating a variety of marketing, manufacturing and distribution
scenarios to determine the most effective and efficient channels to facilitate
the product's worldwide growth.

Ideally, we hope to find partner companies, with regulatory, marketing and
distribution expertise within certain international markets, to commit the human
and financial resources to ensure aggressive and broad launches. Critical to
Cobalis' partner selection is to create relationships that leverage what we hope
will be the most effective and efficient channels in the international
marketplace, while maximizing value growth for the company. We have not yet
entered into any such partnership agreements, however we are in an advanced
state of discussions with several potential major players in this space, and
hope to have an agreement concluded in Q4 2004.

OUR COMPETITION. The market for allergy relief preparations which we intend to
enter is characterized by intense competition. We will be competing against
established pharmaceutical companies which currently market products which are
equivalent or functionally similar to those we intend to market. We estimate
that prices of drug products are significantly affected by competitive factors
and tend to decline as competition increases. In addition, our management
believes that numerous companies are developing or may, in the future, engage in
the development of products that could be competitive with our proposed
products. We expect that technological developments will occur at a rapid rate
and that competition is likely to intensify as the demand for over the counter
and cost-competitive allergy relief preparations grows. We seek to enhance our
competitive position by distinguishing our product as a preventative allergy
treatment from those that mitigate symptoms once they occur.

There are numerous companies that currently sell proprietary allergy
preparations. We estimate that those holding the majority of market share in
this industry are Schering-Plough HealthCare Products Inc., Pfizer Inc., and
Aventis Pharmaceuticals Inc. and GlaxoSmithKline, and others. Many of these
competitors have established histories of operation and greater financial
resources than we have, enabling them to finance acquisition and development
opportunities, to pay higher prices for the same opportunities or to develop and
support their own operations. In addition, many of these companies have greater
name recognition. These companies might be willing to sacrifice profitability to
capture a greater portion of the market for similar products, or pay higher
prices than we would for the same expansion and development opportunities.
Consequently, we may encounter significant competition in our efforts to achieve
our internal growth objectives.

In our estimation, the vast majority of the allergy products currently on the
market are antihistamines which attack allergy symptoms after the histamines
impact the body. We believe that the mechanism of effect for PreHistin (TM) is
completely different in that it prevents the over production of histamines and,
therefore, prevents the allergy symptoms caused by airborne allergens.
Therefore, we hope to create a niche product and distinguish ourselves from our
competitors in that manner.

We believe that, based on retailer feedback, consumer focus groups and extensive
marketing research, PreHistin (TM) can enjoy success because it is a different
type of product than what is currently available. We also believe that our
proposed product addresses the concerns and desires of the consumer in that, in
our estimation it has no side effects while offering a long lasting,
preventative solution to allergy symptoms. Schering-Plough's Claritin is, by
far, the market leader as an OTC medicine (as it was as a prescription
medication). Although we are not yet selling our product, and therefore occupy
no competitive position with regard to the market for allergy relief
preparations, we believe that PreHistin (TM) has the ability to gain a
significant market share from consumers that have tried and/or currently use,
Claritin due to the efficacy and the benefits.

GOVERNMENT REGULATION. We believe that we will experience minimal direct costs
and effects of compliance with environmental laws and other such federal, state
and local regulations, in that we intend to outsource all manufacturing and
distribution operations to companies that comply with Good Manufacturing
Practice Regulations and other applicable laws and regulations. We believe we
are otherwise in compliance with existing or probable governmental regulations
on our business, which include regulations relative to the approval of our
products for sale as a nutritional supplements, over-the-counter medications or
prescription medications.

FDA APPROVAL. Government regulation in the United States is a significant factor
in the production and marketing of new drugs. The FDA must approve all new
over-the-counter and prescription drugs, which includes any new use for a
substance even if previously used safely for a different purpose. In the US,
companies are subject to rigorous requirements in order to engage in the human
clinical testing that must be conducted to gain approval for a drug. To begin
clinical testing, a company must comply with mandatory procedures and safety
standards established by the FDA and apply to the FDA for consent. The
application requires a summary of previous work carried out on drug
characterization, toxicity and safety; as well as an in-depth description of the
proposed clinical trials, which occur in following three phases:

      o  Phase I trials are designed to measure the early safety profile and the
         pattern of drug distribution and metabolism.
      o  Phase II trials are aimed at determining preliminary efficacy and
         optimal dosage, and to expand the evidence regarding safety.
      o  Phase III trials are conducted to provide enough data for statistical
         evaluation of efficacy and safety.

We believe that Cyanocobalamin, PreHistin (TM)'s primary active ingredient, has
been extensively studied and has an excellent safety record. In addition, we
also believe that Cyanocobalamin has no upper dosage limit, has no known side
effects and has no known negative drug interactions. We plan Phase III clinical
studies on PreHistin (TM) for the final quarter of 2004. Protocols for Phase III
trials are currently being finalized and the studies are anticipated to begin
during the winter of 2004; based on our study design which has been approved by
the FDA for a prophylaxis study.



                                       7
<PAGE>

OUR RESEARCH AND DEVELOPMENT. During the each of the last two fiscal years, we
have no expenditures for research and development activities, as all of our
research and development to date was completed prior to fiscal year 2001.
Because our product is not yet in production, there are no costs borne by
customers.

FUTURE PRODUCTS. In addition to PreHistin (TM), Cobalis plans on developing and
marketing additional related products. The products are in various stages of
development and hopefully will provide a continuous stream of corporate growth
for the next several years. Cobalis believes that as revenues and profits
increase, the research and development expense percentage will remain constant,
hopefully enabling Cobalis to capture opportunities to acquire products,
technology and/or companies that assimilate in to the overall corporate
strategy.

Cobalis has additional products in development using the PreHistin (TM)
technology. Cobalis anticipates niche extension products through supplemental
uses, such as for children, seniors, allergic asthma sufferers, animals and
others, and additional patented delivery mechanisms, such as a patch, liposome
spray and other methods. Cobalis hopes that as it increases its brand
recognition in the consumer marketplace, expanding the product line will
increase revenues.


DISCUSSIONS TO ACQUIRE INNOFOOD/MODOFOOD: On July 28, 2003, we entered into a
Stock Exchange Agreement ("Agreement") with InnoFood Inc. ("InnoFood") wherein
we agreed, among other things, to provide InnoFood with Funding totaling
$5,000,000 in exchange for, among other things, 100% interest in InnoFood.
InnoFood is owner of certain rights to a proprietary food processing technology
developed by Modofood S.P.A. of Brescia, Italy. The agreement provided that we
were to have the exclusive distribution rights (through the acquisition of
InnoFood) of Modofood's proprietary food sterilization and preservation
technology for North America, Central America, South America and Japan, as well
as the exclusive rights to negotiate on behalf of Modofood for Southeast Asia,
including Taiwan, China and Indonesia.


                                       8
<PAGE>


The completed purchase of InnoFood was not to occur until the $5,000,000 funding
was delivered. Under the Agreement, we were obligated to provide InnoFood with
the Funding on or before December 31, 2003. Due to what we consider to be
significant breaches of the agreement by InnoFood, we were unwilling to provide
the required funding by the December 31, 2003 deadline. We did provide InnoFood
with $2,220,000. We have confirmed that $1,850,000 of the funds provided to
InnoFood was sent to Modofood S.P.A., an Italian company ("Modofood"). InnoFood
originally entered into a Licensing Agreement with Modofood to market and
distribute Modofood's food processing technology. On October 17, 2003, we
entered into a Letter of Understanding ("LOU") with InnoFood to restructure the
relationship between ourselves and InnoFood. We believe that InnoFood may have
misled our management regarding certain material matters. As a result, the
definitive agreements were never prepared and parties did not finalize the
matters referenced in the LOU.

On January 8, 2004, InnoFood sent us a letter terminating the original InnoFood
Agreement and the October 17, 2003, LOU. InnoFood claimed that we breached both
the Agreement and the LOU by failing to provide the funding provided for under
those agreements. With the letter of termination, InnoFood delivered a signed
Promissory Note agreeing to pay back $2,160,000 (net of $60,000 interest
InnoFood charged to us for non-payments). The Promissory Note accrues interest
at 10% and is due and payable on or before January 15, 2009. As of July 14,
2004, we have not accepted the terms of this promissory note and are still in
negotiation with InnoFood regarding the purchase or some other mutually
acceptable resolution. We believe that InnoFood breached not only the InnoFood
Agreement but also the LOU. We intend to vigorously pursue InnoFood, but have
not determined whether or not we will file suit against InnoFood. We are also in
discussions with Modofood, the technology licensor, regarding potential
resolution directly with that company. If needed, we may also consider pursuing
legal action against Modofood if we are unable to resolve these matters
informally with either company. In the meantime, we are attempting to resolve
this dispute without court intervention.

As of March 31, 2004, we fully reserved the $2,220,000 acquisition deposits due
to uncertainty of the collections. We are vigorously pursuing all legal avenues
with our legal counsel in Italy.

If we are unable to arrive at a satisfactory resolution, we may need to expend
additional resources to litigate this matter.

FACILITIES. Our executive, administrative and operating offices are located at
2445 McCabe Way, Suite 150, Irvine, California, 92614, which represent our only
facilities. We have a lease for this space which runs for three years through
March 31, 2006, with 5,455 square feet of space at a cost of $10,365.50 per
month. We believe these facilities are adequate for our current and projected
requirements as we intend to outsource all manufacturing and distribution.

ITEM 2.  DESCRIPTION OF PROPERTY.
---------------------------------

PROPERTY HELD BY US. As of the date specified in the following table, we held
the following property:

============================== ===================== =========================
Property                           March 31, 2004          March 31, 2003
------------------------------ --------------------- -------------------------
Cash and Equivalents                  $76,181                 $2,290
------------------------------ --------------------- -------------------------
Property and Equipment, net           $63,510                 $57,425
============================== ===================== =========================


OUR FACILITIES. Our executive, administrative and operating office is located at
2445 McCabe Way, Suite 150, Irvine, CA 92614. We have a three year lease for
these premises, which through March 31, 2006. The premises consist of 5,455
square feet of space at a cost of $10,365.50 per month. We believe that our
facilities are adequate for our needs and that additional suitable space will be
available on acceptable terms as required. We do not own any real estate.

ITEM 3.  LEGAL PROCEEDINGS.
---------------------------

The following are legal actions pending against us and those we contemplate
entering into at this time:

Former Leased Office Space: We are a defendant in a suit brought by our former
landlord for breach of lease agreement and alleged unpaid rent. We believe that
our security deposit and other collateral will be sufficient to cover this claim
should an adverse ruling result, even though we anticipate a favorable outcome


                                       9
<PAGE>

to this suit. In addition, we are in the process of submitting cross-claims for
damages incurred and are also appealing the Court's recent ruling denying
Arbitration per the parties' Arbitration Agreement. The landlord recently
obtained a writ of attachment in the amount of $58,840, which remains contested,
and the landlord's Motion for Summary Judgment was denied. However, to reflect
this contingency, we have accrued $60,000 for a potential judgment in this case.

InnoFood/Modofood: On July 28, 2003, we entered into a Stock Exchange Agreement
("Agreement") with InnoFood Inc. ("InnoFood") wherein we agreed, among other
things, to provide InnoFood with Funding totaling $5,000,000 in exchange for,
among other things, 100% interest in InnoFood. The completed purchase of
InnoFood was not to occur until the $5,000,000 funding was delivered. Under the
Agreement, we were obligated to provide InnoFood with the funding on or before
December 31, 2003. Due to what we consider to be significant breaches by
InnoFood, we were unwilling to provide the required funding by the December 31,
2003 deadline. We did provide InnoFood with $2,220,000. We have confirmation
that $1,850,000 of the funds provided to InnoFood was sent to Modofood S.P.A.,
an Italian company ("Modofood"). InnoFood originally entered into a Licensing
Agreement with Modofood to market and distribute Modofood's food processing
technology. On October 17, 2003, we entered into a Letter of Understanding
("LOU") with InnoFood to restructure the relationship between ourselves and
InnoFood. We believe that InnoFood may have misled our management regarding
certain material matters. As a result, the definitive agreements were never
prepared and parties did not finalize the matters referenced in the LOU.

On January 8, 2004, InnoFood sent us a letter terminating the original InnoFood
Agreement and the October 17, 2003 LOU. InnoFood claimed that we breached both
the Agreement and the LOU by failing to provide the funding called for under
those agreements. With the letter of termination, InnoFood delivered a signed
Promissory Note agreeing to pay back $2,160,000 (net of $60,000 interest
InnoFood charged to us for non-payments). The Promissory Note accrues interest
at 10% and is due and payable on or before January 15, 2009. As of March 24,
2004, we have not accepted the terms of this promissory note and are still in
negotiation with InnoFood regarding the purchase or some other mutually
acceptable resolution. We believe that InnoFood breached not only the InnoFood
Agreement but also the LOU. We intend to vigorously pursue InnoFood, but have
not determined whether or not we will file suit against InnoFood. We are also in
discussions with Modofood, the technology licensor, regarding potential
resolution directly with that company. If needed, we may also consider pursuing
legal action against Modofood if we are unable to resolve these matters
informally with either company. In the meantime, we are attempting to resolve
this dispute without court intervention. As of March 31, 2004, we fully reserved
the $2,220,000 acquisition deposits due to uncertainty of the collections. We
are vigorously pursuing all legal avenues with our legal counsel in Italy.

IBCG. We retained Callari & Summers as our litigation counsel to file an action
in Los Angeles County Superior Court against International Business Consultants,
GmbH ("IBCG"). The complaint, filed on April 16, 2004, alleges the following: In
July 2003, pursuant to a loan agreement, IBCG was issued 3,000,000 shares of our
common stock (the "Stock") as collateral for a loan. However, in breach of the
agreement, IBCG did not deliver the loan proceeds and refuses to return the
Stock. By means of this lawsuit, we sought to rescind the loan agreement
and obtain a court order requiring the return or cancellation of the Stock. As
of July 9, 2004, these shares were cancelled pursuant to the Court's order.

Tradename Dispute. A trademark infringement and unfair competition suit against
us was filed in November 2003 by Biogen Idec MA Inc. ("Biogen") in the U.S.
District Court for the District of Massachusetts, file # C.A. 03-123-5 PBS. We
also believe that a default judgment was entered against us on February 9, 2004.
On or about March 22, 2004, we agreed with Biogen to settle the dispute.
According to documents received from by us, on April 14, 2004, Biogen undertook
to file a motion for stay of consideration of its motion for entry of default
judgment and has prepared a consent judgment to be filed with the court.
Pursuant to the consent judgment, we will be enjoined from using "Biogentec" or


                                       10
<PAGE>

"Biogentech" or any phonetic equivalent, and will consent to change our
corporate name to Cobalis Corp. as soon as practicable and to discontinue all
uses of the trade name and trademarks and domain names containing "Biogentech,"
or "Biogentec" and transfer the rights to any domain names we may own containing
"Biogentech" or "Biogentec" to Biogen as soon as practicable. We estimate that
the costs of transferring the domain name registrations and changing the
corporate name will be minimal, and will undertake to change our corporate name
by means of a shareholder vote to be conducted as soon as practicable. As of
April 14, 2004, we have executed a settlement agreement with Biogen which
specifies that we will effect these changes by May 31, 2004 or as soon
thereafter as practicable.

Consumer Survey Center Dispute. A suit was filed against us and our president in
regard to market research and product pricing research services rendered by
Consumer Survey Center, Inc. ("CSC"). CSC is apparently claiming that we owe
$34,900 for services provided by CSC. CSC is also claiming that our president,
Chaslav Radovich, personally guaranteed the debt. The suit was filed on December
17, 2003 in the Superior Court of California, County of San Mateo for breach of
contract. CSC has tentatively agreed to accept stock for the debt; however, as
of March 30, 2004 the parties have not reduced their agreement to writing.

ITEM 4.  SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS
----------------------------------------------------------

Not applicable.

                                     PART II

ITEM 5.  MARKET PRICE FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
------------------------------------------------------------------------

REPORTS TO SECURITY HOLDERS. We are a reporting company with the Securities and
Exchange Commission, or SEC. The public may read and copy any materials filed
with the SEC at the SEC's Public Reference Room at 450 Fifth Street N.W.,
Washington, D.C. 20549. The public may also obtain information on the operation
of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC
maintains an Internet site that contains reports, proxy and information
statements, and other information regarding issuers that file electronically
with the SEC. The address of that site is http://www.sec.gov.

PRICES OF COMMON STOCK. We participate in the OTC Bulletin Board, an electronic
quotation medium for securities traded outside of the Nasdaq Stock Market, and
prices for our common stock are published on the OTC Bulletin Board under the
trading symbol "CBSC". This market is extremely limited and the prices quoted
are not a reliable indication of the value of our common stock.

Approximately seventeen (17) professional market makers hold themselves out as
willing to make a market in our common stock. Following is information about the
range of high and low bid prices for our common stock for each fiscal quarter
since our stock commenced trading. These quotations reflect inter-dealer prices,
without retail mark-up, mark-down or commission, and may not necessarily
represent actual transactions.

--------------------------------------------------------------------------
  QUARTER ENDED           HIGH BID QUOTATION        LOW BID QUOTATION

--------------------------------------------------------------------------
9/30/02*               $        .01            $            .01
--------------------------------------------------------------------------
12/31/02*              $        .05            $            .05
--------------------------------------------------------------------------
3/31/03 *              $        .01            $            .01
--------------------------------------------------------------------------
6/30/03*               $        .05            $            .05
--------------------------------------------------------------------------
9/30/03                $       3.80            $            3.75
--------------------------------------------------------------------------
12/31/03               $       3.50            $            3.50
--------------------------------------------------------------------------
3/31/04                $       1.90            $            1.55
--------------------------------------------------------------------------
* Quoted market price prices are for shares of our stock prior to the
reverse-merger with Biogentec effective July 2, 2003.


                                       11
<PAGE>

We are authorized to issue 50,000,000 shares of $.001 par value common stock and
5,000,000 shares of $.001 par value preferred stock. As of June 16, 2004, there
were one hundred seventy two record holders of our common stock and there were
24,368,983 shares of our common stock issued and outstanding. There are no other
outstanding options or warrants to purchase securities convertible into, shares
of our common stock, except for the following:

We have 750,000 exercisable options to purchase shares of our common stock
currently outstanding, of which 400,000 were granted in 2003 and 350,000 which
were granted in 2004.

In February 2004, we agreed to grant Mr. Ernest Armstrong, one of our officers
and principal shareholders, 1,200,000 options to purchase shares of our common
stock. In addition, St. Petka Trust, our majority shareholder, agreed to grant
to Mr. Armstrong 1,000,000 options to purchase shares of our common stock that
it owns.

We have agreed to register for sale a total of 1,910,834 shares of our common
stock underlying the convertible note and warrants issued to Gryphon pursuant to
a financing agreement, as described herein, along with 305,000 shares already
issued to Gryphon pursuant to the terms of those agreements. There have been no
cash dividends declared on our common stock. Dividends are declared at the sole
discretion of our Board of Directors. There are 1,000 shares of our preferred
stock issued and outstanding.

EQUITY COMPENSATION PLANS. We have no securities authorized for issuance under
any equity compensation plans or similar arrangements.
<TABLE>
<CAPTION>
----------------------------- ------------------------ --------------------------- ----------------------------------
       PLAN CATEGORY           NUMBER OF SECURITIES    WEIGHTED-AVERAGE EXERCISE    NUMBER OF SECURITIES REMAINING
                                 TO BE ISSUED UPON        PRICE OF OUTSTANDING       AVAILABLE FOR FUTURE ISSUANCE
                                    EXERCISE OF          OPTIONS, WARRANTS AND      UNDER EQUITY COMPENSATION PLANS
                               OUTSTANDING OPTIONS,              RIGHTS             (EXCLUDING SECURITIES REFLECTED
                                WARRANTS AND RIGHTS                                         IN COLUMN (a))
                                        (a)                        (b)                             (c)
----------------------------- ------------------------ --------------------------- ----------------------------------
             <S>                        <C>                       <C>                              <C>
Equity compensation plans
approved by security holders            N/A                       N/A                             N/A
----------------------------- ------------------------ --------------------------- ----------------------------------
Equity compensation plans
not approved by security              750,000                     1.62                            N/A
holders
----------------------------- ------------------------ --------------------------- ----------------------------------
Total                                 750,000                     1.62                            N/A
----------------------------- ------------------------ --------------------------- ----------------------------------
</TABLE>

Penny stock regulation. Shares of our common stock will probably be subject to
rules adopted by the Securities and Exchange Commission that regulate
broker-dealer practices in connection with transactions in "penny stocks". Penny
stocks are generally equity securities with a price of less than $5.00, except
for securities registered on certain national securities exchanges or quoted on
the Nasdaq system, provided that current price and volume information with
respect to transactions in those securities is provided by the exchange or
system. The penny stock rules require a broker-dealer, prior to a transaction in
a penny stock not otherwise exempt from those rules, deliver a standardized risk
disclosure document prepared by the Securities and Exchange Commission, which
contains the following:

o    a description of the nature and level of risk in the market for penny
     stocks in both public offerings and secondary trading;
o    a description of the broker's or dealer's duties to the customer and of the
     rights and remedies available to the customer with respect to violation to
     such duties or other requirements of securities' laws;
o    a brief, clear, narrative description of a dealer market, including "bid"
     and "ask" prices for penny stocks and the significance of the spread
     between the "bid" and "ask" price;


                                       12
<PAGE>


o    a toll-free telephone number for inquiries on disciplinary actions;
o    definitions of significant terms in the disclosure document or in the
     conduct of trading in penny stocks; and
o    such other information and is in such form, including language, type, size
     and format, as the Securities and Exchange Commission shall require by rule
     or regulation.

Prior to effecting any transaction in penny stock, the broker-dealer also must
provide the customer the following:

o    the bid and offer quotations for the penny stock;
o    the compensation of the broker-dealer and its salesperson in the
     transaction;
o    the number of shares to which such bid and ask prices apply, or other
     comparable information relating to the depth and liquidity of the market
     for such stock; and
o    monthly account statements showing the market value of each penny stock
     held in the customer's account.

In addition, the penny stock rules require that prior to a transaction in a
penny stock not otherwise exempt from those rules, the broker-dealer must make a
special written determination that the penny stock is a suitable investment for
the purchaser and receive the purchaser's written acknowledgment of the receipt
of a risk disclosure statement, a written agreement to transactions involving
penny stocks, and a signed and dated copy of a written suitably statement. These
disclosure requirements may have the effect of reducing the trading activity in
the secondary market for a stock that becomes subject to the penny stock rules.
Holders of shares of our common stock may have difficulty selling those shares
because our common stock will probably be subject to the penny stock rules.

ITEM 6.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR PLAN
OF OPERATION.
-----------------------------------------------------------------------------

THIS FOLLOWING INFORMATION SPECIFIES CERTAIN FORWARD-LOOKING STATEMENTS OF
MANAGEMENT OF THE COMPANY. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT
ESTIMATE THE HAPPENING OF FUTURE EVENTS ARE NOT BASED ON HISTORICAL FACT.
FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING
TERMINOLOGY, SUCH AS "MAY", "SHALL", "COULD", "EXPECT", "ESTIMATE",
"ANTICIPATE", "PREDICT", "PROBABLE", "POSSIBLE", "SHOULD", "CONTINUE", OR
SIMILAR TERMS, VARIATIONS OF THOSE TERMS OR THE NEGATIVE OF THOSE TERMS. THE
FORWARD-LOOKING STATEMENTS SPECIFIED IN THE FOLLOWING INFORMATION HAVE BEEN
COMPILED BY OUR MANAGEMENT ON THE BASIS OF ASSUMPTIONS MADE BY MANAGEMENT AND
CONSIDERED BY MANAGEMENT TO BE REASONABLE. OUR FUTURE OPERATING RESULTS,
HOWEVER, ARE IMPOSSIBLE TO PREDICT AND NO REPRESENTATION, GUARANTY, OR WARRANTY
IS TO BE INFERRED FROM THOSE FORWARD-LOOKING STATEMENTS.

THE ASSUMPTIONS USED FOR PURPOSES OF THE FORWARD-LOOKING STATEMENTS SPECIFIED IN
THE FOLLOWING INFORMATION REPRESENT ESTIMATES OF FUTURE EVENTS AND ARE SUBJECT
TO UNCERTAINTY AS TO POSSIBLE CHANGES IN ECONOMIC, LEGISLATIVE, INDUSTRY, AND
OTHER CIRCUMSTANCES. AS A RESULT, THE IDENTIFICATION AND INTERPRETATION OF DATA
AND OTHER INFORMATION AND THEIR USE IN DEVELOPING AND SELECTING ASSUMPTIONS FROM
AND AMONG REASONABLE ALTERNATIVES REQUIRE THE EXERCISE OF JUDGMENT. TO THE
EXTENT THAT THE ASSUMED EVENTS DO NOT OCCUR, THE OUTCOME MAY VARY SUBSTANTIALLY
FROM ANTICIPATED OR PROJECTED RESULTS, AND, ACCORDINGLY, NO OPINION IS EXPRESSED
ON THE ACHIEVABILITY OF THOSE FORWARD-LOOKING STATEMENTS. NO ASSURANCE CAN BE
GIVEN THAT ANY OF THE ASSUMPTIONS RELATING TO THE FORWARD-LOOKING STATEMENTS
SPECIFIED IN THE FOLLOWING INFORMATION ARE ACCURATE, AND WE ASSUME NO OBLIGATION
TO UPDATE ANY SUCH FORWARD-LOOKING STATEMENTS.

CRITICAL ACCOUNTING POLICY AND ESTIMATES.
-----------------------------------------

Our Management's Discussion and Analysis of Financial Condition and Results of
Operations section discusses our financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States
of America. The preparation of these financial statements requires management to
make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. On an on-going basis,
management evaluates its estimates and judgments, including those related to
revenue recognition, accrued expenses, financing operations, and contingencies
and litigation. Management bases its estimates and judgments on historical
experience and on various other factors that are believed to be reasonable under


                                       13
<PAGE>

the circumstances, the results of which form the basis for making judgments
about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under
different assumptions or conditions. The most significant accounting estimates
inherent in the preparation of our financial statements include estimates as to
the appropriate carrying value of certain assets and liabilities which are not
readily apparent from other sources, primarily valuation of patent costs and
stock-based compensation. The methods, estimates and judgments we use in
applying these most critical accounting policies have a significant impact on
the results we report in our consolidated financial statements.

Patent Cost Valuation. The determination of the fair value of certain acquired
assets and liabilities is subjective in nature and often involves the use of
significant estimates and assumptions. Determining the fair values and useful
lives of intangible assets especially requires the exercise of judgment. While
there are a number of different generally accepted valuation methods to estimate
the value of intangible assets acquired, we primarily use the weighted-average
probability method outlined in SFAS 144. This method requires significant
management judgment to forecast the future operating results used in the
analysis. In addition, other significant estimates are required such as residual
growth rates and discount factors. The estimates we have used are consistent
with the plans and estimates that we use to manage our business, based on
available historical information and industry averages. The judgments made in
determining the estimated useful lives assigned to each class of assets acquired
can also significantly affect our net operating results.

Stock-based Compensation. We record stock-based compensation to outside
consultants at fair market value in general and administrative expense. We do
not record expense relating to stock options granted to employees with an
exercise price greater than or equal to market price at the time of grant. We
report pro-forma net loss and loss per share in accordance with the requirements
of SFAS 123 and 148. This disclosure shows net loss and loss per share as if we
had accounted for our employee stock options under the fair value method of
those statements. Pro-forma information is calculated using the Black-Scholes
pricing method at the date of grant. This option valuation model requires input
of highly subjective assumptions. Because our employee stock options have
characteristics significantly different from those of traded options, and
because changes in the subjective input assumptions can materially affect the
fair value estimate, in management's opinion, the existing model does not
necessarily provide a reliable single measure of fair value of our employee
stock options.

Estimate of Litigation-based Liability. We are defendant in certain claims and
litigations in the ordinary course of business (see "Legal Proceedings"). We
accrue liabilities relating to these lawsuits on a case-by-case basis. We
generally accrue attorney fees and interest in addition to the liability being
sought. Liabilities are adjusted on a regular basis as new information becomes
available. We consult with its attorneys to determine the viability of an
expected outcome. The actual amount paid to settle a case could differ
materially from the amount accrued.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In January 2003, the FASB issued FASB Interpretation No. 46, "Consolidation of
Variable Interest Entities, an Interpretation of Accounting Research Bulletin
(ARB) No. 51". This interpretation clarifies the application of ARB No. 51,
"Consolidated Financial Statements," to certain entities in which equity
investors do not have the characteristics of a controlling financial interest or
do not have sufficient equity at risk for the entity to finance its activities
without additional subordinated financial support from other parties. In
December 2003, the FASB revised FASB Interpretation No. 46 (FIN 46R) which
addresses certain implementation issues and allowed companies with certain types
of variable interest entities to defer adoption of FIN 46R until the end of the
first interim or annual reporting period ending after March 15, 2004. We are
evaluating the impact of applying FIN 46R to our consolidated financial
statements.


                                       14
<PAGE>

In December 2003, the Securities and Exchange Commission ("SEC") issued Staff
Accounting Bulletin ("SAB") No. 104, "Revenue Recognition." SAB 104 supersedes
SAB 101, "Revenue Recognition in Financial Statements." SAB 104's primary
purpose is to rescind accounting guidance contained in SAB 101 related to
multiple element revenue arrangements, superseded as a result of the issuance of
EITF 00-21, "Accounting for Revenue Arrangements with Multiple Deliverables."
Additionally, SAB 104 rescinds the SEC's Revenue Recognition in Financial
Statements Frequently Asked Questions and Answers ("the FAQ") issued with SAB
101 that had been codified in SEC Topic 13, Revenue Recognition. Selected
portions of the FAQ have been incorporated into SAB 104. While the wording of
SAB 104 has changed to reflect the issuance of EITF 00-21, the revenue
recognition principles of SAB 101 remain largely unchanged by the issuance of
SAB 104, which was effective upon issuance. The adoption of SAB 104 did not
impact the consolidated financial statements.

LIQUIDITY AND CAPITAL RESOURCES

We had cash and equivalents of $76,181 at March 31, 2004. We also had $11,619 in
prepaid and other current assets and $5,903 in inventory making our total
current assets at March 31, 2004 equal to $93,703. We also had the following
long term assets: $67,882 in debt issue costs; $63,510 in property and
equipment, net, $6,575 in net website development costs, and $734,329
represented by net value of our patents, $40,000 in deposits. Therefore, our
total assets as of March 31, 2004 were $1,005,999.

Our total current liabilities were $4,226,595 at March 31, 2004, which was
represented by accounts payable of $552,062 and $947,084 of accrued expenses,
$1,262,448 due to related parties, warrant liability of $142,138, convertible
note payable of $107,863, after a discount of $492,137 and demand loans payable
for $1,215,000. Our liabilities exceeded our assets by $3,220,596 as of March
31, 2004.

We have financed our operations primarily through cash generated from related
party debt financing and from the private placement sales of equity securities.
We also sold Common Stock in the amount of $200,000, Preferred Stock in the
amount of $885,000, as well as issuing a Convertible Debenture with proceeds in
the amount of $600,000. Additionally related parties loaned an additional
$563,650 to us. Also during the year ended March 31, 2004, we had $1,215,000 in
demand loans payable.

Our cash used in investing activities was $2,146,612 for the year ended March
31, 2004, as compared to $145,699 for the same period ended in 2003, an increase
of $2,000,913, which was due to the InnoFood acquisition deposit.

Our net cash provided by financing activities was $3,302,350 for the year ended
March 31, 2004 compared to $757,325 for the same period a year earlier. The
increase of $2,545,025 is primarily due to proceeds from demand loans payable,
the sale of preferred stock, and convertible note payable, and increases in the
sale of common stock and loan proceeds from related parties. Restatement of
Prior Year Financial Statements

As discussed in Note 2 to the consolidated financial statement, we entered into
agreements with Gene Pharmaceuticals LLC ("GP LLC") to purchase certain patents
and other assets. We previously had valued the patents based on the present
value of the minimum contractual obligations using a 6% discount rate. Per the
December 19, 2002 agreement, we issued to GP LLC 2,000,000 shares of our common
stock in exchange for the minimum contractual payments. At this time we valued
the transaction based on the deemed current value of our common stock, which
resulted in us increasing the carrying value of the patents by $1,658,378. At
the time our stock was not publicly traded so we valued its stock at $2.00 per
share which was the most recent price that we had sold shares for cash. After
this increase in the value of patents, the patents carrying value was
$3,905,832. At March 31, 2003, the patents were appraised at $3,850,000 which
resulted in us writing down the value of the patents by $55,832.

We have restated our previously issued consolidated financial statements to
reflect using a discount rate of 15.5% rather than 6% to value the minimum
contractual obligations and to value the 2,000,000 shares of common stock issued
in the December 19, 2002 transaction at the carrying value of the contractual
obligation that was exchanged for the shares rather than at the deemed current
value of the shares at the date of issuance.

In addition, we did not amortize the value of our patents. The consolidated
financial statements have been restated to reflect the amortization of our
patents over the estimated useful life of the patents using the straight line
method. Amortization expense for the years ended March 31, 2001, 2002 and 2003
was $20,458, $84,690 and $87,161, respectively.


                                       15
<PAGE>


The effects of the restatement are as follows:
                                                  AS PREVIOUSLY
                                                     FILED         AS RESTATED

    March 31, 2001
         Patents                                 $   2,222,744   $   1,100,756
         Accumulated amortization of patents     $           -   $      20,458
         Contract payable                        $   2,206,422   $   1,092,530
         Total Stockholders' equity              $      76,117   $      47,565
         Net loss                                $    (194,864)  $    (223,416)


    March 31, 2002
         Patents                                 $   2,246,005   $  1,124,017
         Accumulated amortization of patents     $           -   $    105,148
         Contract payable                        $   2,259,533   $  1,176,802
         Total Stockholders' deficit             $    (260,911)  $   (405,315)
         Net loss                                $  (1,028,397)  $ (1,144,249)


    March 31, 2003
         Patents                                 $   3,850,000   $   1,125,466
         Accumulated amortization of patents     $           -   $     192,309
         Total Stockholders' equity              $   3,418,865   $     502,022
         Net loss                                $  (2,087,652)  $  (2,148,008)


RESULTS OF OPERATIONS FOR THE YEAR ENDED MARCH 31, 2004 AS COMPARED TO THE
YEAR ENDED MARCH 31, 2003

Revenues and Cost of Sales

We had no significant revenues for the years ended March 31, 2004 and March 31,
2003 as we are undertaking a Phase III clinical trial in order to obtain FDA
approval of PreHistin (TM) as an over the counter drug. Our net sales were
$4,708 less $12,402 for cost of sales for a gross loss of $7,694 for the year
ended March 31, 2004 as compared net sales of $447 less $10,440 for cost of
sales for a gross loss of $9,993 for the restated year ended March 31, 2003.

Operating Expenses

Operating expenses for the year ended March 31, 2004 were $4,554,669 compared to
$2,012,738 for the year ended March 31, 2003. For both years, expenses incurred
were for two major purposes: i) ongoing development of our PreHistin (TM)
product and related product management and ii) general management and fund
raising efforts. For the year ended March 31, 2004, this amount was represented
by $116,158 in depreciation and amortization, $738,257 in professional fees,
$789,383 in salary and wages, $125,680 in rent expense, $150,083 in marketing
and promotions, $2,331,552 in impairment expense and $305,586 in other operating
expenses, as compared to the year ended March 31, 2003, where we had $109,971 in
depreciation and amortization, $852,902 in professional fees, $530,486 in salary
and wages, $112,106 in rent expense, $171,974 in marketing and promotions, $0 in
impairment expense and $235,299 in other operating expenses. Our operating
expenses increased due primarily to our impairment expense related to the write
off of the acquisition deposit to InnoFood and the writedown of the value of one
of our patents, increased compensation and consulting expenses.


                                       16
<PAGE>

Interest expense and financing costs for the year ended March 31, 2004 were
$1,350,617 compared to $125,277 for the year ended March 31, 2003. The
significant increase is due to the interest on the convertible note payable, the
demand note payable and the advances from related parties. In addition, the
amortization of debt issue costs and debt discounts and penalties for not
registering shares underlying the conversion of the convertible note payable and
convertible preferred stock.

The change in the fair value in the warrant liability relates to the decrease in
the value of the detachable warrants issued in connection with the convertible
note payable and convertible preferred stock. Due to the decline our stock
price, the fair value of these warrants has decreased resulting in the decrease
of the warrant liability.

During the year ended March 31, 2004, we recognized $885,000 of a preferred
stock dividend relating to the issuance of convertible preferred stock. (See
Note 6). Preferred stock dividend represented the relative fair value of
warrants and beneficial conversion features in relation to the issuance of the
convertible preferred stock. Our net loss attributable to common shareholders
for year ended March 31, 2004, before the preferred dividend was $5,703,639.

OUR PLAN OF OPERATION FOR THE NEXT TWELVE MONTHS.

Over the next 12 months, we plan to continue moving forward with the Phase III
clinical trials of our allergy prevention product, PreHistin (TM), followed
immediately by submission of an application to the FDA for marketing approval of
PreHistin (TM) as an over the counter ("OTC") allergy medication. We hope to
receive approval from the FDA in late 2005, enabling our US marketing launch of
the product for the spring 2006 allergy season.

While continuing with the US FDA approval process, we are working to finalize
the international launch strategy in the primary global markets. Discussions are
progressing with potential joint venture partners for marketing, manufacturing,
regulatory approval and distribution throughout the world, the most advanced of
which are with companies in Japan and Canada.

In addition to seeking approval from the FDA for the primary indication of
seasonal allergic rhinitis (hay fever) for PreHistin (TM), we plan to conduct
additional studies to validate the viability of approval for supplemental
indications and alternative delivery mechanisms. The tests will be a combination
of clinical trials and laboratory analyses.

We are also actively pursuing the acquisition and development of products that
we hope will enable us to leverage our resources. Areas of focus are OTC
pharmaceutical products and nutritional supplements.

As of March 31, 2004, we had cash of $76,181. To fully execute our business plan
for the next 12 months, we will need to raise additional funds in order to
complete the Phase III clinical trials, submit the PreHistin (TM) application to
the United States FDA and to execute a marketing launch of the PreHistin (TM)
product. We will also need to raise funds to execute studies for the further
development of the PreHistin (TM) product line and to complete the acquisition
of additional products. Along with our investment bankers, we plan to raise
these funds through private and institution or other equity offerings. We may
attempt to secure other loans from lending institutions or other sources. There
is no guarantee that we will be able to raise additional funds through offerings
or other sources. If we are unable to raise funds, our ability to continue with
product development will be hindered.

Other than the research and development related to our PreHistin (TM) product,
we do not plan to engage in any other research and development unless we are
able to raise additional funds. We do anticipate the purchase of significant
equipment within the next 12 months for our PreHistin (TM) product. We do not
anticipate any significant hiring over the next 12 months.

Off-balance sheet arrangements. There are no off balance sheet arrangements that
have or are reasonably likely to have a current or future effect on our
financial condition, changes in financial condition, revenues or expenses,
results of operations, liquidity, capital expenditures or capital resources that
are material to investors.


                                       17
<PAGE>

ITEM 7.  FINANCIAL STATEMENTS
-----------------------------

The financial statements required by Item 7 are presented in the copy filed on
EDGAR.


                          Cobalis Corp. and Subsidiary
                          (a Development Stage Company)
                        Consolidated Financial Statements
                       Years Ended March 31, 2004 and 2003
                    And from November 21, 2000 (inception) to
                                 March 31, 2004


<TABLE>
<CAPTION>
                                    CONTENTS

                                                                                                        PAGE
<S>                                                                                                      <C>
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM                                                  F-1

FINANCIAL STATEMENTS:
     Consolidated Balance Sheet as of March 31, 2004                                                     F-2
     Consolidated Statements of Operations for the years ended March 31, 2004 and 2003,
       and from November 21, 2000 (inception) to March 31, 2004                                          F-3
     Consolidated Statement of Stockholders' Deficit for the period from
       November 21, 2000 (Inception) to March 31, 2004                                                   F-4
     Consolidated Statements of Cash Flows for the years ended March 31, 2004 and 2003,
       and from November 21, 2000 (inception) to March 31, 2004                                          F-5
     Notes to Consolidated Financial Statements                                                          F-9
</TABLE>




                                       18
<PAGE>



             Report of Independent Registered Public Accounting Firm


Cobalis Corp. (formerly Biogentech Corp.)
Irvine, California

We have audited the accompanying consolidated balance sheets of Cobalis Corp.
(formerly Biogentech Corp.) (a Development Stage Company) as of March 31, 2004,
and the related consolidated statements of operations, stockholders' deficit,
and cash flows for each of the two years in the period ended March 31, 2004 and
the period from November 21, 2000 (inception) to March 31, 2004. These
consolidated financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the
consolidated financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as well
as evaluating the overall consolidated financial statement presentation. We
believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of the Company as of
March 31, 2004, and the results of its operations and its cash flows for each of
the two years in the period ended March 31, 2004 and the period from November
21, 2000 (inception) to March 31,2004, in conformity with U.S. generally
accepted accounting principles.

The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 1 to the
consolidated financial statements, the Company has losses from operations, has
not generated significant revenue, and has a working capital deficit. These
factors raise substantial doubt about its ability to continue as a going
concern. Management's plans in regard to these matters are also described in
Note 1. The consolidated financial statements do not include any adjustments
that might result from the outcome of this uncertainty.




/s/ Stonefield Josephson, Inc.
CERTIFIED PUBLIC ACCOUNTANTS

Irvine, California
July 8, 2004



                                       19
<PAGE>



            Cobalis Corp. (formerly Biogentech Corp.) and Subsidiary
                          (A Development Stage Company)
                           Consolidated Balance Sheet



                          Cobalis Corp. and Subsidiary
                          (A Development Stage Company)
                           Consolidated Balance Sheet
                              As of March 31, 2004


<TABLE>
<CAPTION>

                                     ASSETS

<S>                                                                                              <C>
CURRENT ASSETS
     Cash                                                                                 $         76,181
     Prepaid expenses and other current assets                                                      11,619
     Inventory                                                                                       5,903

                                                                                          -----------------
TOTAL CURRENT ASSETS                                                                                93,703

DEBT ISSUE COSTS                                                                                    67,882
PROPERTY AND EQUIPMENT, net of accumulated depreciation of $48,548                                  63,510
WEBSITE DEVELOPMENT COSTS, net of accumulated amortization of $24,500                                6,575
PATENTS, net of accumulated amortization of $170,986                                               734,329
DEPOSIT                                                                                             40,000

                                                                                          -----------------
TOTAL ASSETS                                                                              $      1,005,999
                                                                                          =================


                      LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
     Accounts payable                                                                     $        552,062
     Accrued expenses                                                                              947,084
     Due to related parties                                                                      1,262,448
     Warrant liability                                                                             142,138
     Convertible note payable, net of discount of $492,137                                         107,863
     Demand loans payable                                                                        1,215,000

                                                                                          -----------------
TOTAL CURRENT LIABILITIES                                                                        4,226,595

7.5% CONVERTIBLE PREFERRED STOCK (dividends in arrears of $37,500)
       $0.001 par value; 1,000 shares authorized; 1,000 shares issued and outstanding              885,000

COMMITMENTS AND CONTINGENCIES                                                                            -

STOCKHOLDERS' DEFICIT
     Common stock; $0.001 par value; 50,000,000 shares
       authorized; 24,119,708 shares issued and 21,119,708 shares outstanding                       21,120
     Additional paid-in capital                                                                  5,977,596
     Deficit accumulated during the development stage                                          (10,104,312)

                                                                                          -----------------
TOTAL STOCKHOLDERS' DEFICIT                                                                     (4,105,596)
                                                                                          -----------------

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                                               $       1,005,999
                                                                                          =================
</TABLE>








             The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       20
<PAGE>




            COBALIS CORP. (FORMERLY BIOGENTECH CORP.) AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF OPERATIONS

                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF OPERATIONS

<TABLE>
<CAPTION>
                                                                YEAR ENDED                 CUMULATIVE FROM
                                                       -------------------------------        NOVEMBER 21,
                                                         MARCH 31,        MARCH 31,      2000 (INCEPTION) TO
                                                           2004             2003           MARCH 31, 2004
                                                       --------------   --------------   --------------------
                                                                         (as restated)      (as restated)
<S>                                                          <C>              <C>                 <C>

NET SALES                                              $       4,708    $         447    $             5,155

COST OF SALES                                                 12,402           10,440                 28,842

                                                       --------------   --------------   --------------------
GROSS LOSS                                                    (7,694)          (9,993)               (23,687)
                                                       --------------   --------------   --------------------

OPERATING EXPENSES:
     Professional fees                                       738,257          852,902              1,953,094
     Salary and wages                                        789,383          530,486              1,701,694
     Rent expense                                            125,680          112,106                283,259
     Marketing and promotions                                150,083          171,974                331,923
     Depreciation and amortization                           116,158          109,971                352,663
     Impairment expense                                    2,331,522                -              2,331,522
     Other operating expenses                                303,586          235,299                752,838
                                                       --------------   --------------   --------------------
TOTAL OPERATING EXPENSES                                   4,554,669        2,012,738              7,706,993
                                                       --------------   --------------   --------------------

LOSS FROM OPERATIONS                                      (4,562,363)      (2,022,731)            (7,730,680)

OTHER INCOME (EXPENSE)
     Interest expense and financing costs                 (1,350,617)        (125,277)            (1,697,973)
     Change in fair value of warrant liability               209,341                -                209,341

                                                       --------------   --------------   --------------------
TOTAL OTHER INCOME (EXPENSE)                              (1,141,276)        (125,277)            (1,488,632)
                                                       --------------   --------------   --------------------

LOSS BEFORE PROVISION FOR INCOME TAXES                    (5,703,639)      (2,148,008)            (9,219,312)

PROVISION FOR INCOME TAXES                                         -                -                      -
                                                       --------------   --------------   --------------------

NET LOSS                                                  (5,703,639)      (2,148,008)            (9,219,312)

PREFERRED STOCK DIVIDENDS                                    885,000                -                885,000
                                                       --------------   --------------   --------------------

NET LOSS ATTRIBUTED TO COMMON STOCKHOLDERS             $  (6,588,639)   $  (2,148,008)   $       (10,104,312)
                                                       ==============   ==============   ====================

NET LOSS PER SHARE:
     BASIC AND DILUTED                                 $      (0.32)    $       (0.12)   $             (0.56)
                                                       ==============   ==============   ====================

WEIGHTED AVERAGE SHARES OUTSTANDING:
     BASIC AND DILUTED                                    20,630,593       17,747,111             18,162,479
                                                       ==============   ==============   ====================
</TABLE>





             The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       21
<PAGE>




            COBALIS CORP. (FORMERLY BIOGENTECH CORP.) AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                 CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 20, 2000 (INCEPTION) TO MARCH 31, 2004



                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT
       FOR THE PERIOD FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004

<TABLE>
<CAPTION>
                                                                                                              DEFICIT
                                                                                                            ACCUMULATED   TOTAL
                                                                                    ADDITIONAL              DURING THE STOCKHOLDERS'
                                                                   COMMON STOCK      PAID-IN     DEFERRED   DEVELOPMENT   EQUITY
                                                                SHARES    AMOUNT     CAPITAL   COMPENSATION    STAGE     (DEFICIT)
                                                                --------  --------  ----------  -----------  ---------   ----------
<S>                                                               <C>       <C>        <C>          <C>         <C>         <C>
Balance at inception (November 21, 2000)                               -  $      -  $        -  $         -  $       -  $         -
Issuance of founder's shares in exchange
  for property and equipment                                  16,300,000    16,300           -            -          -       16,300
Issuance of common stock for cash - November 2000 @ $1.00         30,000        30      29,970            -          -       30,000
Issuance of common stock for cash - December 2000 @ $1.00         15,000        15      14,985            -          -       15,000
Issuance of common stock for cash - February 2001 @ $1.00         12,000        12      11,988            -          -       12,000
Issuance of common stock for cash - March 2001 @ $1.00           125,000       125     124,875            -          -      125,000
Issuance of common stock for services - March 2001 @ $1.00        10,000        10       9,990            -          -       10,000
Contributed capital                                                    -         -      62,681            -          -       62,681
Net loss for the period from inception                                                                               -
  (November 21, 2000) to March 31, 2001                                -         -           -            -   (223,416)    (223,416)
                                                                --------  --------  ----------  -----------  ---------   ----------

Balance at March 31, 2001, as restated                        16,492,000    16,492     254,489            -   (223,416)      47,565

Issuance of common stock for cash - April 2001 @ $1.00            10,000        10       9,990            -          -       10,000
Issuance of common stock for telephone equipment -
  April 2001 @ $1.00                                               6,750         7       6,743            -          -        6,750
Issuance of common stock for cash - May 2001 @ $1.00              11,000        11      10,989            -          -       11,000
Issuance of common stock for website development -
  May 2001 @ $1.00                                                17,000        17      16,983            -          -       17,000
Issuance of common stock for legal services -
  May 2001 @ $1.00                                                 1,000         1         999            -          -        1,000
Issuance of common stock for cash - June 2001 @ $1.00             23,500        24      23,476            -          -       23,500
Issuance of common stock for cash - July 2001 @ $1.00             20,000        20      19,980            -          -       20,000
Issuance of common stock for cash - August 2001 @ $1.00           25,000        25      24,975            -          -       25,000
Issuance of common stock for services, related party -
  September 2001 @ $1.00                                          65,858        66      65,792            -          -       65,858
Issuance of common stock for cash - September 2001 @ $1.00        15,000        15      14,985            -          -       15,000
Issuance of common stock for services - September 2001            11,000        11      10,989            -          -       11,000
Issuance of stock options for services - September 2001                -         -      32,000            -          -       32,000
Issuance of common stock for cash - October 2001 @ $1.00           5,000         5       4,995            -          -        5,000
Issuance of common stock for cash - December 2001 @ $1.00         30,000        30      29,970            -          -       30,000
Issuance of common stock for services -
  December 31, 2001 @ $1.00                                       33,000        33      32,967            -          -       33,000
Issuance of common stock for services, related party -
  December 2001 @ $1.00                                          117,500       118     117,382            -          -      117,500
Issuance of common stock for prepaid advertising -
  December 2001 @ $1.00                                           15,600        15      15,585            -          -       15,600
Issuance of common stock for property and equipment -
  January 2002 @ $3.00                                             1,000         1       2,999            -          -        3,000
Issuance of common stock for services, related party -
  January 2002 @ $1.00                                            33,000        33      32,967            -          -       33,000
Issuance of common stock for cash - February 2002 @ $2.00         20,000        20      39,980            -          -       40,000
Issuance of common stock for cash - March 2002 @ $2.00            12,500        12      24,988            -          -       25,000
Contributed capital                                                    -         -     211,269            -          -      211,269
Deferred compensation                                                  -         -           -      (60,108)         -      (60,108)
Net loss                                                               -         -           -            - (1,144,249)  (1,144,249)
                                                                --------  --------  ----------  -----------  ---------   ----------

Balance at March 31, 2002, as restated                        16,965,708    16,966   1,005,492      (60,108)(1,367,665)    (405,315)

Issuance of common stock for services - April 2002 @ $2.00         3,000         3       5,997            -          -        6,000
Issuance of common stock for cash - April 2002 @ $1.00            10,000        10       9,990            -          -       10,000
Issuance of common stock for cash - April 2002 @ $2.00            17,500        17      34,983            -          -       35,000
Issuance of common stock for cash - May 2002 @ $1.00              10,000        10       9,990            -          -       10,000
Issuance of common stock for cash - May 2002 @ $2.00              16,000        16      31,984            -          -       32,000
Issuance of stock options for services - May 2002                      -         -     350,000            -          -      350,000
Contributed capital - bonus expense                                    -         -      50,000            -          -       50,000
Issuance of common stock for cash - June 2002 @ $1.00              5,000         5       4,995            -          -        5,000
Issuance of common stock for cash - June 2002 @ $2.00              5,000         5       9,995            -          -       10,000
Issuance of common stock for cash - July 2002 @ $1.00              5,000         5       4,995            -          -        5,000
Issuance of common stock for cash - August 2002 @ $2.00           10,000        10      19,990            -          -       20,000
Issuance of common stock for cash - September 2002 @ $2.00        10,000        10      19,990            -          -       20,000
Issuance of stock options below fair market value - November 2002      -         -     250,000     (250,000)         -            -
Issuance of common stock for conversion of note -
   December 2002 @ $2.00                                          50,000        50      99,950            -          -      100,000
Issuance of common stock for cash - December 2002 @ $2.00         20,000        20      39,980            -          -       40,000
Issuance of common stock for services - December 2002 @ $2.00     15,000        15      29,985            -          -       30,000
Issuance of common stock to pay off contract payable -
   December 2002 @ $0.64                                       2,000,000     2,000  $1,285,917            -          -    1,287,917
Contributed capital                                                                    292,718            -          -      292,718
Issuance of common stock for exercise of options -December 2002  574,000       574     574,028            -          -      574,602
Deferred compensation                                                  -         -           -       60,108          -       60,108
Contributed capital                                                    -         -       5,000            -          -        5,000
Issuance of common stock for services - January 2003                   -         -      25,000            -          -       25,000
Issuance of common stock for cash February 2003 @ $2.00           11,500        12      22,988            -          -       23,000
Issuance of common stock for cash March 2003 @ $2.00               5,000         5       9,995            -          -       10,000
Deferred compensation                                                  -         -           -       54,000          -       54,000
Net loss                                                               -         -           -            -  (2,148,008) (2,148,008)
                                                                --------  --------  ----------  -----------  ---------   ----------

Balance at March 31, 2003, as restated                        19,732,708    19,733   4,193,962     (196,000) (3,515,673)    502,022

Issuance of common stock for cash April 2003 @ $2.00              70,000        70     139,930            -          -      140,000
Issuance of common stock for cash May 2003 @ $2.00                30,000        30      59,970            -          -       60,000
Acquisition by Biogentech Corp of ("Togs for Tykes")           1,032,000     1,032    (101,032)           -          -     (100,000)
Issuance of common stock for penalties  January 2004 @ $2.80     135,000       135     377,865            -          -      378,000
Issuance of common stock for services February 2004 @ $2.20      100,000       100     219,900            -          -      220,000
Issuance of common stock for services February 2004 @ $1.85      $20,000        20      36,980            -          -       37,000
Value of beneficial converstion feature of convertible
  debenture issued in September 2003                                   -         -     346,870            -          -      346,870
Fair value allocated to warrant liability for detachable
  warrants issued with preferred stock                                 -         -    (181,849)           -          -     (181,849)
Dividend on preferred stock                                            -         -     885,000            -   (885,000)           -
Deferred compensation                                                  -         -           -      196,000          -      196,000
Net loss                                                               -         -           -            - (5,703,639)  (5,703,639)
                                                                --------  --------  ----------  -----------  ---------   ----------

Balance at March 31, 2004                                     21,119,708  $ 21,120  $5,977,596  $         -$(10,104,312)$(4,105,596)
                                                                ========  ========  ==========  ===========  =========    ==========
</TABLE>






             The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       22
<PAGE>




            COBALIS CORP. (FORMERLY BIOGENTECH CORP.) AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS



                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
                                                                                         CUMULATIVE FROM
                                                            YEAR ENDED                     NOVEMBER 21,
                                                             MARCH 31,     MARCH 31,     2000 (INCEPTION) TO
                                                              2004            2003       MARCH 31, 2004
                                                           ------------   -------------  ----------------
                                                                          (as restated)   (as restated)
<S>                                                            <C>             <C>              <C>
CASH FLOW FROM OPERATING ACTIVITIES:
   Net loss                                              $  (5,703,639)     (2,148,008)   $   (9,219,312)
   Adjustment to reconcile net loss to net cash
    provided by (used in) operating activities:
      Depreciation and amortization expense                    116,158         109,971           352,663
      Common stock issued for services                         257,000          36,000           564,358
      Common stock issued for penalty                          378,000               -           378,000
      Change in value of warrant liability                    (209,341)              -          (209,341)
      Amortization of debt issue costs                          15,618               -            15,618
      Exercise of stock options for services                                    26,960            26,960
      Amortization of discounts on notes                        24,363          93,089           297,991
      Issuance of stock options for services                         -         375,000           407,000
      Capital contribution - bonus (related party)                   -          50,000            50,000
      Amortization of prepaid advertising                            -          11,700            15,600
      Amortization of deferred compensation                    196,000         114,108           250,000
      Discount on common stock issued for settlement of debt         -          50,000            50,000
      Impairment expense                                     2,331,522               -         2,331,522
   Changes in assets and liabilities:                                                                  -
    Prepaid expenses and other assets                           (8,133)         12,714           (11,619)
    Inventory                                                       97          (5,750)              347
    Accounts payable                                            94,988         283,840           520,345
    Accrued expenses                                           947,084               -           947,084
    Amounts due to related parties                             478,436         373,943         1,124,123
                                                           ------------   -------------  ----------------
Net cash used in operating activities                       (1,081,847)       (616,433)       (2,108,661)
                                                           ------------   -------------  ----------------

CASH FLOWS FROM INVESTING ACTIVITIES:
   Purchase of property and equipment                          (25,937)         (3,499)          (86,007)
   Increase in patent costs                                          -          (1,450)          (24,711)
   Change in restricted cash                                   100,000        (100,000)                -
   Merger fees and costs                                             -               -                 -
   Increase in acquisition deposits                         (2,220,000)              -        (2,220,000)
   Increase in other deposits                                        -         (40,000)          (40,000)
   Increase in capitalized website                                (675)           (750)          (14,565)

                                                           ------------   -------------  ----------------
Net cash used in investing activities                       (2,146,612)       (145,699)       (2,385,283)
                                                           ------------   -------------  ----------------

CASH FLOW FROM FINANCING ACTIVITIES:
   Payment on contract                                               -         (11,000)         (161,000)
   Proceeds from advances - related party                      563,650         255,607           869,257
   Proceeds from issuance of notes payable                   1,215,000               -         1,215,000
   Proceeds from sale of common stock                          200,000         220,000           806,500
   Proceeds from sale of preferred stock                       885,000               -           885,000
   Proceeds from convertible debenture                         600,000               -           600,000
   Capital contribution                                              -         297,718           571,668
   Payment of debt issue costs                                 (83,500)              -           (83,500)
   Payments on advances - related party                        (77,800)         (5,000)         (132,800)

                                                           ------------   -------------  ----------------
Net cash provided by financing activities                    3,302,350         757,325         4,570,125
                                                           ------------   -------------  ----------------

NET INCREASE (DECREASE) IN CASH AND
   CASH EQUIVALENTS                                             73,891          (4,807)           76,181

CASH, beginning of the year                                      2,290           7,097                 -
                                                           ------------   -------------  ----------------

CASH, end of the year                                      $    76,181    $      2,290    $       76,181
                                                           ============   =============  ================

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

   Interest paid                                           $         -    $          -    $            -
                                                           ============   =============  ================
   Income taxes paid                                       $         -    $          -    $            -
                                                           ============   =============  ================
</TABLE>





             The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       23
<PAGE>



            COBALIS CORP. (FORMERLY BIOGENTECH CORP.) AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)



SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

         FOR THE PERIOD FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2002

         The Company issued 16,300,000 shares of its common stock at par, as
         founder's shares, for property and equipment, totaling $16,300, upon
         formation of the Company.

         The Company issued a note payable as consideration for the purchase of
         patents and inventory valued at $1,086,536 and $6,250, respectively.
         The Company recorded a $2,843,464 discount on note payable relating to
         the issuance of the note.

         The Company issued 10,000 shares of its common stock for consulting
         services totaling $10,000, which represented the fair market value on
         the date of issuance.

         During the period from November 21, 2000 (inception) to March 31, 2002,
         R&R, a shareholder of the Company, advanced the Company cash and also
         paid certain expenses directly on behalf of the Company totaling
         $273,950. The Company has recorded these transactions as a contribution
         to capital as of March 31, 2001.

         The Company issued 6,750 shares of its common stock valued at $6,750
         for telephone equipment, which represented the fair market value on the
         date of issuance.

         The Company issued 17,000 shares of its common stock valued at $17,000
         for website development costs, which represented the fair market value
         on the date of issuance.

         The Company issued 45,000 shares of its common stock valued at $45,000
         for legal and consulting services provided, which represented the fair
         market value on the date of issuance.

         The Company issued 216,358 shares of its common stock valued at $1.00
         per share or $216,358 as consideration for past and future consulting
         services provided by a related party, which represented the fair market
         value on the date of issuance. This resulted in the Company recording
         $60,108 of deferred compensation as of March 31, 2002.

         The Company issued 15,600 shares of its common stock valued at $15,600
         for prepaid advertising expense, which represents the fair market value
         on the date of issuance.

         During January 2002, the Company issued 1,000 shares of its common
         stock for property and equipment with a fair value of $3,000.

         The Company issued 64,000 options to officers of the Company, to
         purchase its common stock at $0.50 per share for services rendered
         totaling $32,000. The Company's common stock had a fair market value of
         $1.00 per share on the date of issuance.



             The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       24
<PAGE>




            COBALIS CORP. (FORMERLY BIOGENTECH CORP.) AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)


SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
(CONTINUED):

         FOR THE YEAR ENDED MARCH 31, 2003

         As of March 31, 2003, the Company has fully amortized the remaining
         balance of deferred compensation in the amount of $60,108 resulting
         from the issuance of common shares for future consulting services.

         The Company issued 18,000 shares of its common stock valued at $36,000
         for consulting services provided, which represented the fair market
         value on the date of issuance.

         During the year ended March 31, 2003, R&R advanced the Company cash and
         also paid certain expenses directly on behalf of the Company totaling
         $292,718. The Company has recorded these transactions as a contribution
         to capital as of March 31, 2003.

         On May 5, 2002, a related party transferred 25,000 shares of the
         Company's common stock valued at $50,000 to an employee of the Company
         as a bonus. The fair market value on the date of issuance was $2.00 per
         share. The Company has recorded this transaction as a contribution to
         capital and salary expense as of March 31, 2003.

         During September 2002, a shareholder loaned the Company $50,000, which
         was convertible into 50,000 shares of the Company's common stock. The
         fair market value of the common stock was $2.00 per share; therefore,
         the Company recorded a $50,000 expense relating to this note.
         Subsequently, on December 31, 2002, the note holder converted the
         $50,000 promissory note into 50,000 shares of the Company's common
         stock.

         During May 2002, the Company granted stock options to three consultants
         to purchase a total of 300,000 shares at an exercise price of $1.00 per
         share. The options vest immediately on the execution date of the
         consulting agreement. At the date of the grant, the fair value of the
         common stock was $2.00 per share. The Company valued these options
         under the Black-Scholes model with a total valuation of approximately
         $350,000, which was included in the statements of operations for the
         year ended March 31, 2003.




              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       25
<PAGE>



            COBALIS CORP. (FORMERLY BIOGENTECH CORP.) AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
(CONTINUED):

         FOR THE YEAR ENDED MARCH 31, 2003 (CONTINUED)
         ----------------------------------------------

         Three employees exercised 574,000 stock options as consideration for
         the forgiveness of $574,602 of accrued salaries to these three
         employees.

         On December 19, 2002, the Company issued 2,000,000 shares of its common
         stock valued at $1,287,917 in lieu of payment in full under the
         contract payable totaling $1,287,917.

         On November 5, 2002, the Company entered into an employment agreement
         with its new Chief Operating Officer ("COO"). The COO received 500,000
         options to purchase 500,000 shares of the Company's common stock an
         exercise price totaling the lesser of $2.00 per share or 75% of the
         fair market value of the Company's common stock on date of grant. As of
         November 5, 2002, the fair market value of the Company's common stock
         was $2.00 per share; therefore, the exercise price of the stock options
         issued was $1.50 per option. The Company recognized deferred
         compensation relating to these options and is amortizing the expense
         over the vesting period. During the year ended March 31, 2003, the
         Company recognized $54,000 of expense relating to these options.

         On December 27, 2002, the Company entered into an employment agreement
         with its Chief Financial Officer ("CFO") on a part-time basis. This
         agreement became effective on January 2, 2003. The CFO was granted
         25,000 fully vested options to purchase 25,000 shares of the Company's
         common stock with an exercise price of $1.00 per share during January
         2003. The fair market value of the common stock was $2.00 per share;
         therefore, during January 2003, the Company recognized $25,000 of
         compensation expense upon issuance.

         FOR THE YEAR ENDED MARCH 31, 2004
         ----------------------------------

         In September 2003, the Company sold a convertible debenture with
         detachable warrants. The Company calculated the value of the warrants
         and the convertible feature of the debenture utilizing the
         Black-Scholes model. The $169,630 value of the warrants is included in
         the warrant liability due to registration rights in accordance with
         EITF 00-19. The $346,870 value of the beneficial conversion debenture
         was charged to additional paid-in capital.

         The Company issued 135,000 shares of its common stock valued at
         $378,000 for a penalty associated with its convertible debenture, which
         represented the fair market value on the date of issuance.

         The Company issued 120,000 shares of its common stock valued at
         $257,000 for consulting services and employee bonus.




             The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       26
<PAGE>



                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004




NOTE 1 - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

         Organization and Line of Business
         ---------------------------------
         BioGentec Incorporated ("BG"), a private Nevada corporation, was
         incorporated on November 21, 2000 according to the laws of Nevada,
         under the name St Petka, Inc. On May 4, 2001, BG formally changed its
         name to BioGentec Incorporated. On July 2, 2003, BG was merged into
         Togs for Tykes Acquisition Corp.("TTAC"), a wholly owned subsidiary
         formed for the purpose of acquiring BG. TTAC is the wholly owned
         subsidiary of the registrant, Cobalis Corp. (formerly Biogentech Corp.
         and formerly Togs for Tykes, Inc.) ("the Company" or "Cobalis"). As
         allowed under SFAS 141, the Company designated a date of convenience of
         the closing for accounting purposes as June 30, 2003. Under the terms
         of the merger agreement, all of BG's outstanding common stock
         (19,732,705 shares of $0.001 par value stock) will be exchanged for
         19,732,705 shares newly issued shares of $0.001 par value stock of
         Cobalis' common stock. At the date of the transaction, BGTH had
         5,532,000 shares of common stock outstanding of which 4,500,000 will be
         cancelled as part of the transaction. The Company changed its corporate
         name to Cobalis Corp. with the filing of a Certificate of Amendment to
         our corporate articles in Nevada on July 6, 2004.

         This transaction was consummated with the filing of the Articles of
         Merger with the State of Nevada on July 2, 2003 BG shareholders then
         effectively controlled approximately 95% of the issued and outstanding
         common stock of Cobalis. Since the shareholders of BG obtained control
         of Cobalis, according to FASB Statement No. 141 - "BUSINESS
         COMBINATIONS," this acquisition has been treated as a recapitalization
         for accounting purposes, in a manner similar to reverse acquisition
         accounting. In accounting for this transaction:

         o        BG is deemed to be the purchaser and surviving company for
                  accounting purposes. Accordingly, its assets and liabilities
                  are included in the balance sheet at their historical book
                  values and the results of operations of BG have been presented
                  for the comparative prior period; and

         o        Control of the net assets and business of Cobalis was acquired
                  for accounting purposes effective June 30, 2003. This
                  transaction has been accounted for as a purchase of the assets
                  and liabilities of Cobalis by BG as of June 30 2003. The
                  historical cost of the net assets acquired was $0 and $100,000
                  cash was paid for costs and fees associated with the merger.

         The Company is a biotechnology company that has purchased the
         intellectual property rights (including related patents) to market
         Immun-Eeze, a dietary supplement, which is a natural alternative to
         over-the-counter and prescription medications. Immun-Eeze is effective
         in alleviating allergies and their accompanying symptoms. Immun-Eeze
         has been reformulated (the reformulation is included in the patent) and
         will be marketed under the name Prehistin, previously "Allertin".




             The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       27
<PAGE>



                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         Basis of Presentation
         ---------------------

         The accompanying consolidated financial statements have been prepared
         in conformity with in accordance with accounting principles generally
         accepted in the United States of America, which contemplate
         continuation of the Company as a going concern. The Company has
         incurred a net loss of $5,703,639 for the year ended March 31, 2004 and
         as of March 31, 2004, the Company had a working capital deficiency of
         $4,132,892 and a stockholder deficit of $4,105,596. In addition, as of
         March 31, 2004, the Company has not developed a substantial source of
         revenue.

         These conditions raise substantial doubt as to the Company's ability to
         continue as a going concern. These consolidated financial statements do
         not include any adjustments that might result from the outcome of this
         uncertainty. These consolidated financial statements do not include any
         adjustments relating to the recoverability and classification of
         recorded asset amounts, or amounts and classification of liabilities
         that might be necessary should the Company be unable to continue as a
         going concern.

         The Company is currently attempting to raise additional debt and equity
         financing for operating purposes.

         The Company requires substantial capital to pursue its operating
         strategy, which includes commercialization of its products, and
         currently has limited cash for operations. Until the Company can obtain
         revenues sufficient to fund working capital needs and additional
         research and development costs necessary to obtain the regulatory
         approvals for commercialization, the Company will be dependent upon
         external sources of financing.

         There can be no assurances that sufficient financing will be available
         on terms acceptable to the Company, or at all. If the Company is unable
         to obtain such financing, the Company will be forced to scale back
         operations, which could have an adverse effect on the Company's
         financial condition and results of operations. These factors raise
         substantial doubt about the Company's ability to continue as a going
         concern.

         Management believes that actions presently being taken to revise the
         Company's operating and financial requirements provide the opportunity
         for the Company to continue as a going concern.

         Principles of Consolidation
         ---------------------------

         The accompanying consolidated financial statements include the accounts
         of Cobalis and its wholly owned subsidiary, BioGentec Inc. The
         accompanying consolidated financial statements have been prepared in
         accordance with accounting principles generally accepted in the United
         States of America. All inter-company accounts and transactions have
         been eliminated in consolidation.



                                       28
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         Use of Estimates
         ----------------

         The preparation of consolidated financial statements in conformity with
         accounting principles generally accepted in the United States of
         America requires management to make estimates and assumptions that
         affect the reported amounts of assets and liabilities and disclosures
         of contingent assets and liabilities at the date of the consolidated
         financial statements and the reported amounts of revenue and expenses
         during the reporting periods. As of March 31, 2004, the Company used
         estimates in determining the realization of its accounts receivable and
         inventory, capitalization and amortization of web development costs and
         patents, and fair value of equity instruments issued for services.
         Actual results could differ from these estimates.

         Fair Value of Financial Instruments
         -----------------------------------

         For certain of the Company's consolidated financial instruments,
         including cash and cash equivalents, accounts payable, accrued
         expenses, and due to related parties, the carrying amounts approximate
         fair value due to their short maturities. The amounts shown for
         convertible debentures and notes payable also approximate fair value
         because current interest rates and terms offered to the Company for
         similar debt are substantially the same.

         Cash and Cash Equivalents
         -------------------------

         For purposes of the consolidated statements of cash flows, the Company
         defines cash equivalents as all highly liquid debt instruments
         purchased with a maturity of three months or less, plus all
         certificates of deposit.

         Concentration of Credit Risk
         ----------------------------

         Financial instruments, which potentially subject the Company to
         concentrations of credit risk, consist of cash and cash equivalents and
         accounts receivables. The Company places its cash with high quality
         financial institutions and at times may exceed the FDIC $100,000
         insurance limit. The Company extends credit based on an evaluation of
         the customer's financial condition, generally without collateral.
         Exposure to losses on receivables is principally dependent on each
         customer's financial condition. The Company monitors its exposure for
         credit losses and maintains allowances for anticipated losses, as
         required. As of March 31, 2004, the Company had approximately $22,000
         exceeding the insurance limit.


                                       29
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         Inventory
         ---------

         Inventory, consisting primarily of sample products used for marketing
         purposes, is carried at the lower of cost or market utilizing the
         first-in, first-out method.

         Property and Equipment
         ----------------------

         Property and equipment are stated at cost and are depreciated using the
         straight-line method over their estimated useful lives of 3 to 7 years
         for various classes of assets. Expenditures for maintenance and repairs
         are charged to operations as incurred while renewals and betterments
         are capitalized. Gains and losses on disposals are included in the
         results of operations.

         The estimated service lives of property and equipment are as follows:
                  Furniture and fixtures:            7 years
                  Computer equipment:                3 to 5 years

         Research and Development
         ------------------------

         The Company incurs costs in the research and development of a dietary
         supplement, Alleratin. All costs relating to phases I and II clinical
         trials were incurred before acquisition of the patents. Phase III and
         other research and development costs are charged to expense as
         incurred. For the years ended March 31, 2004 and 2003 and the period
         form November 21, 2000 (inception) to March 31, 2004, the Company
         incurred $66,871, $18,412, and $91,753, respectively, in research and
         development expenses.

         Website Development Costs
         -------------------------

         Website development costs are for the development of the Company's
         Internet website. These costs have been capitalized when acquired and
         installed, and are being amortized over three years. The Company
         accounts for these costs in accordance with EITF 00-2, "Accounting for
         Website Development Costs," which specifies the appropriate accounting
         for costs incurred in connection with the development and maintenance
         of websites. Amortization expense totaled $9,000, $9,000, and $24,500,
         respectively, for the years ended March 31, 2004 and 2003 and the
         period from November 21, 2000 (inception) to March 31, 2004.

         Patent Costs
         ------------

         Patent costs are carried at cost less accumulated amortization, which
         is calculated on a straight-line basis, over the estimated economic
         life of the patent. In accordance with SFAS No. 142, "Goodwill and
         Other Intangible Assets," the Company evaluates intangible assets and
         other long-lived assets (including patent costs) for impairment, at
         least on an annual basis and whenever events or changes in
         circumstances indicate that the carrying value may not be recoverable
         from its estimated future cash flows. Recoverability of intangible
         assets and other long-lived assets is measured by comparing their net


                                       30
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         book value to the related projected undiscounted cash flows from these
         assets, considering a number of factors including past operating
         results, budgets, economic projections, market trends and product
         development cycles. If the net book value of the asset exceeds the
         related undiscounted cash flows, the asset is considered impaired, and
         a second test is performed to measure the amount of impairment loss.
         During the year ended March 31, 2004, the Company recognized an
         impairment expense of $111,522 related to one of its patents as it
         determined that this patent had no future value based on its assessment
         of expected future cash flows to be generated by this patent and the
         results of an independent appraisal done in April 2004. Amortization
         expense related to these patents for the years ended March 31, 2004 and
         2003 and the period from November 21, 2000 (inception) to March 31,
         2004 was $87,306, $87,161 and $279,615, respectively. Projected
         amortization expense approximates $54,000, $54,000, $49,000, $49,000
         and $49,000, respectively, for each of the five years ended March 31,
         2009. Weighted average life of the remaining patent approximated 17.7
         years.

         Revenue Recognition
         -------------------

         The Company will recognize revenue from product sales when shipment of
         product to the customer has been made, which is when title passes. The
         Company will estimate and record provisions for rebates, sales returns
         and allowances in the period the sale is recorded. Shipping and
         handling charges are included in gross sales, with the related costs
         included in selling, general and administrative expenses. For the years
         ended March 31, 2004 and 2003, the Company had not generated any
         significant revenue.

         Impairment of Long-Lived Assets
         -------------------------------

         In accordance with SFAS Nos. 142 and 144, long-lived assets to be held
         and used are analyzed for impairment whenever events or changes in
         circumstances indicate that the carrying amount of an asset may not be
         recoverable. SFAS No. 142 relates to assets with an indefinite life
         where as SFAS 144 relates to assets that can be amortized and the life
         determinable. The Company evaluates at each balance sheet date whether
         events and circumstances have occurred that indicate possible
         impairment. If there are indications of impairment, the Company uses
         future undiscounted cash flows of the related asset or asset grouping
         over the remaining life in measuring whether the assets are
         recoverable. In the event such cash flows are not expected to be
         sufficient to recover the recorded asset values, the assets are written
         down to their estimated fair value. Long-lived assets to be disposed of
         are reported at the lower of carrying amount or fair value of asset
         less the cost to sell.

         Stock Based Compensation
         ------------------------

         SFAS No. 123, "Accounting for Stock-Based Compensation," establishes
         and encourages the use of the fair value based method of accounting for
         stock-based compensation arrangements under which compensation cost is
         determined using the fair value of stock-based compensation determined
         as of the date of grant and is recognized over the periods in which the
         related services are rendered. The statement also permits companies to
         elect to continue using the current intrinsic value accounting method
         specified in Accounting Principles Board ("APB") Opinion No. 25,



                                       31
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         "Accounting for Stock Issued to Employees," to account for stock-based
         compensation. The Company has elected to use the intrinsic value based
         method and has disclosed the pro forma effect of using the fair value
         based method to account for its stock-based compensation issued to
         employees. For options granted to employees where the exercise price is
         less than the fair value of the stock at the date of grant, the Company
         recognizes an expense in accordance with APB 25. For non-employee stock
         based compensation the Company recognizes an expense in accordance with
         SFAS No. 123 and values the equity securities based on the fair value
         of the security on the date of grant. For stock-based awards the value
         is based on the market value for the stock on the date of grant and if
         the stock has restrictions as to transferability a discount is provided
         for lack of tradability. Stock option awards are valued using the
         Black-Scholes option-pricing model.

         If the Company had elected to recognize compensation expense based upon
         the fair value at the grant date for awards under the Stock Option Plan
         consistent with the methodology prescribed by SFAS No. 123, the
         Company's net loss and loss per share would be reduced to the pro forma
         amounts indicated below for the year ended March 31, 2004 and 2003:
<TABLE>
<CAPTION>
                                                                         2004               2003 (as restated)
                                                                  ------------------  -------------------
            <S>                                                           <C>                <C>
         Net loss to common stockholders
           As reported                                            $      (6,588,639)  $       (2,148,008)
           Compensation recognized under APB 25                                   -              79,000
           Compensation recognized under SFAS 123                        (2,177,776)             (90,000)
                                                                  ------------------  -------------------
                      Pro forma                                   $      (8,766,415)  $       (2,159,008)
                                                                  ==================  ==================


         Basic and diluted loss per common share

           As reported                                            $           (0.32)  $           (0.12)
           Pro forma                                              $           (0.42)  $           (0.12)


         The fair value for these options was estimated at the date of grant
         using a Black-Scholes option pricing model with the following
         weighted-average assumptions for 2004 and 2003:

                                                                        2004                 2003
                                                                --------------------  ---------------------

         Risk-free interest rate:                                      4.1%                5.6%
         Dividend yields:                                                0%                  0%
         Volatility factors:                                            75%                  0%
         Weighted average expected life of the option:                 3.5 years         2.5 years
</TABLE>
         In February 2004, the Company's majority shareholder, St. Petka Trust,
         granted 1,000,000 options to an employee of the Company. The Company
         accounted for the transactions between St. Petka Trust and this
         employee in accordance with Staff Bulletin Board (SAB) 5T, "Accounting
         for Expenses or Liabilities Paid by Principal Stockholder(s)" which
         requires the Company to record expense for services paid by the
         stockholder for the benefit of the Company. Since the strike price of
         the options is higher than the market price of the Company's stock on
         the date of the grant, no expense was recorded in accordance with APB
         25. The fair value of the options approximates $989,898 under the SFAS
         123 which is included in the calculation of the proforma net loss.


                                       32
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004



         Advertising and Marketing Costs
         -------------------------------

         Advertising costs are expensed as incurred and included in operating
         expenses. For the years ended March 31, 2004 and 2003 and for the
         period from November 21, 2000 (inception) to March 31, 2004,
         advertising costs were $150,083 and $171,974, and $331,923,
         respectively.


         Income Taxes
         ------------

         The Company accounts for income taxes in accordance with SFAS No. 109,
         "Accounting for Income Taxes." Deferred taxes are provided on the
         liability method whereby deferred tax assets are recognized for
         deductible temporary differences, and deferred tax liabilities are
         recognized for taxable temporary differences. Temporary differences are
         the differences between the reported amounts of assets and liabilities
         and their tax bases. Deferred tax assets are reduced by a valuation
         allowance when, in the opinion of management, it is more likely than
         not that some portion or all of the deferred tax assets will not be
         realized. Deferred tax assets and liabilities are adjusted for the
         effects of changes in tax laws and rates on the date of enactment.

         Loss Per Share
         --------------

         The Company reports earnings (loss) per share in accordance with SFAS
         No. 128, "Earnings per Share." Basic earnings (loss) per share is
         computed by dividing income (loss) available to common shareholders by
         the weighted average number of common shares available. Diluted
         earnings (loss) per share is computed similar to basic earnings (loss)
         per share except that the denominator is increased to include the
         number of additional common shares that would have been outstanding if
         the potential common shares had been issued and if the additional
         common shares were dilutive. Diluted earnings (loss) per share has not
         been presented since the effect of the assumed conversion of options
         and warrants to purchase common shares would have an anti-dilutive
         effect. The Company has excluded all outstanding options, warrants, and
         convertible note payable and preferred stock from the calculation of
         diluted net loss per share because these securities are anti-dilutive.
         As of March 31, 2004 and 2003, the Company has approximately 3,260,834
         and 1,150,000 common stock equivalents, respectively.

         Comprehensive Loss
         ------------------

         SFAS No. 130, "Reporting Comprehensive Income," establishes standards
         for the reporting and display of comprehensive income and its
         components in the financial statements. For the years ended March 31,
         2004 and 2003 and the period from November 21, 2000 (inception) to
         March 31, 2004, the Company has no items that represent comprehensive
         income and, therefore, has not included a schedule of comprehensive
         income in the financial statements.


                                       33
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         Discount on Convertible Note Payable and Preferred Stock
         --------------------------------------------------------

         Discounts on convertible note payable and preferred stock are the
         relative fair values attributed to the detachable warrants issued and
         the value of the beneficial conversion features associated with the
         convertible note payable and preferred stock. These discounts are
         accounted for in accordance with Emerging Issues Task Force ("EITF")
         00-27, "Application of Issue No. 98-5 to Certain Convertible
         Instruments." issued by the American Institute of Certified Public
         Accountants.

         Warrant Liability
         -----------------

         Pursuant to EITF 00-19, "Accounting for Derivative Financial
         Instruments Indexed to, and Potentially Settled in, a Company's Own
         Stock", the Company has recorded the relative fair value of warrants
         issued with registration rights on the Convertible Debenture and the
         Convertible Preferred Stock in the amount of $351,479 as a short-term
         liability until the Company has obtained an effective registration
         statement for these shares.

         Additionally, the Company is required to report a value of the warrant
         as a fair market value and record the fluctuation to the fair value of
         the warrant liability to current operations. The fair value decreased
         by $209,341 during the year ended March 31, 2004 and such amount has
         been included in other income.

         Payroll Tax Liability
         ---------------------

         The Company has not remitted approximately $89,000 in payroll tax
         liabilities that are recorded in accrued expenses in the accompanying
         consolidated balance sheet.

         Recently Issued Accounting Pronouncements
         -----------------------------------------

          In January 2003, the FASB issued FASB Interpretation No. 46,
         "Consolidation of Variable Interest Entities, an Interpretation of
         Accounting Research Bulletin (ARB) No. 51". This interpretation
         clarifies the application of ARB No. 51, "Consolidated Financial
         Statements," to certain entities in which equity investors do not have
         the characteristics of a controlling financial interest or do not have
         sufficient equity at risk for the entity to finance its activities
         without additional subordinated financial support from other parties.
         In December 2003, the FASB revised FASB Interpretation No. 46 (FIN 46R)
         which addresses certain implementation issues and allowed companies
         with certain types of variable interest entities to defer adoption of
         FIN 46R until the end of the first interim or annual reporting period
         ending after March 15, 2004. The Company is evaluating the impact of
         applying FIN 46R to its consolidated financial statements.

         In December 2003, the Securities and Exchange Commission ("SEC") issued
         Staff Accounting Bulletin ("SAB") No. 104, "Revenue Recognition." SAB
         104 supersedes SAB 101, "Revenue Recognition in Financial Statements."
         SAB 104's primary purpose is to rescind accounting guidance contained
         in SAB 101 related to multiple element revenue arrangements, superseded
         as a result of the issuance of EITF 00-21, "Accounting for Revenue
         Arrangements with Multiple Deliverables." Additionally, SAB 104


                                       34
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004



         rescinds the SEC's Revenue Recognition in Financial Statements
         Frequently Asked Questions and Answers ("the FAQ") issued with SAB 101
         that had been codified in SEC Topic 13, Revenue Recognition. Selected
         portions of the FAQ have been incorporated into SAB 104. While the
         wording of SAB 104 has changed to reflect the issuance of EITF 00-21,
         the revenue recognition principles of SAB 101 remain largely unchanged
         by the issuance of SAB 104, which was effective upon issuance. The
         adoption of SAB 104 did not impact the consolidated financial
         statements.


NOTE 2 - ACQUISITION OF CERTAIN ASSETS

         On November 22, 2000, the Company entered into an asset purchase
         agreement to acquire certain tangible and intangible assets from Gene
         Pharmaceuticals, LLC, formerly known as Allergy Limited, LLC ("GP
         LLC"), an unrelated company. As consideration, the Company agreed to
         pay a $150,000 down payment, as well as royalty payments calculated as
         a percentage of gross sales of the product known as "Immune-Eeze,"
         occurring on or after January 1, 2001. The royalty payments were to be
         computed and payable quarterly, beginning with the quarter ended March
         31, 2001, at the greater of the:

        (i)   Buyers Minimum Royalty Obligation;
        (ii)  rate of 6% of annual gross sales on the first $50,000,000 in
              gross sales; and
        (iii) rate of 3% of annual gross sales on all gross sales in excess of
              $50,000,000.

         The Company's minimum royalty obligation to GP LLC in the event that
         gross sales in any quarter did not meet certain threshold amounts would
         total $3,930,000. The minimum guaranteed purchase price was payable
         through 2022.

         Gross sales are defined as all payments received by the Company on
         worldwide sales of all products containing Vitamin B12 including, but
         not limited to, sales of all products in pediatric doses and for use by
         domestic animals.

         Per the asset purchase agreement, the Company had the option to buy the
         patent outright with no royalty or future minimum royalty payments for
         the following:

         $5,000,000 through June 30, 2002; $6,000,000 from July 1, 2002 to June
         30, 2003; $7,000,000 from July 1, 2003 to June 30, 2004; or $8,000,000
         thereafter.

         The tangible and intangible assets purchased resulted in the recording
         of $6,250 of inventory, $1,080,286 of patents as of November 22, 2000,
         and, since the minimum royalty payments did not include interest, the
         Company has recorded a discount on the contract payable totaling
         $2,843,464, using an interest rate of 15.5%, which was being amortized
         over the life of the payable.


                                       35
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         Per the asset purchase agreement, the Company has secured the rights to
         two patents, which were valued at their fair market values as of the
         date of purchase. The patents are for the introduction of, or
         "delivery" of, Cyanocobalamin, via a lozenge, and cover the various
         forms of B12 used to provide relief from allergy and bronchial asthma
         symptoms. The U.S. patent expires in 2009. Additional U.S. and foreign
         patents covering the use of lozenges delivering B12 for allergic
         diseases are in effect until 2018. In July 2001, the Company was
         granted a Notice of Entitlement intended to expand geographic coverage
         of the two existing patents. Amortization was calculated on a
         straight-line basis over the shorter of the remaining economic life or
         estimated lives of the patents.

         Recognition of contingent royalty payments above the guaranteed
         purchase price will be expensed in the period they are incurred.

         As of March 31, 2002, the Company was in default on the minimum
         guaranteed payments. On April 20, 2002, payments relating to the
         minimum guaranteed purchase price were extended without penalty until
         May 31, 2002, at which time the first payment was due and payable. On
         June 1, 2002, the Company again defaulted on the agreement.

         Per the asset purchase agreement, in event of default on any of the
         royalty or minimum royalty payments to the seller and such default is
         not cured with in 120 days, all purchased assets would revert back to
         GP LLC.

         On December 19, 2002, GP LLC and the Company entered into a new
         memorandum of agreement whereby they amended the terms of the original
         asset purchase agreement whereby the purchase price shall be as
         follows:

          a) the sum of all amounts previously paid by the Company under the
             asset purchase agreement totaling $161,000;
          b) the outstanding contractual obligation for minimum royalty payments
             be settled for the issuance of 2,000,000 shares of the Company's
             common stock valued; and
          c) a royalty calculated at 1.5% of the gross sales of the product, as
             defined above.

         Royalty payments shall commence to accrue on December 19, 2002, and
         will be computed and payable quarterly. For the years ended March 31,
         2004 and 2003 and the period from November 21, 2000 (inception) to
         March 31, 2004, no royalty expense was accrued due to insignificant
         amount of sales for the periods.

         As a result, the Company satisfied its indebtedness to GP LLC, and
         reduced its future royalty obligation related to the patents in
         exchange for the 2,000,000 shares of the Company's common stock.

         Also see Note 11 as the Company has restated its consolidated financial
         statements as a result of changes in the way it has accounted for this
         transaction with GP LLC.


                                       36
<PAGE>



                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004



NOTE 3 - PROPERTY AND EQUIPMENT
<TABLE>
<CAPTION>
         The cost of property and equipment at March 31, 2004 consisted of the
         following:
                     <S>                                                                  <C>
                  Furniture and fixtures                                            $       71,500
                  Office equipment                                                          40,558
                                                                                    ---------------
                                                                                           112,058
                  Less accumulated depreciation and amortization                           (48,548)
                                                                                    ---------------
                                                                                    $       63,510
                                                                                    ===============
         Depreciation expense for the years ended March 31, 2004 and 2003 and
         the period from November 21, 2000 (inception) to March 31, 2004 was
         $19,852, $13,810 and $48,548, respectively.


NOTE 4 - DUE TO RELATED PARTIES

         Due to related parties at March 31, 2004 consists of the following:

                           R&R Holdings, Inc. (a)                                   $      943,756
                           Chaslav Radovich (b)                                            154,500
                           Other officers/executives (c)                                   164,192
                                                                                    --------------
                                                                                    $    1,262,448
                                                                                    ==============
</TABLE>


         (a) On January 1, 2001, the Company entered into a consulting contract
         with R&R Development, Inc. DBA R&R Holdings, Inc. ("R&R") whereby they
         would provide managerial consulting services to the Company at the rate
         of $125,000 per year and the rate shall increase to $135,000 per year
         when and if the Company completes a merger with a public shell company.
         R&R is also a shareholder of the Company. As of March 31, 2004, the
         Company had accrued $208,642 of consulting fees relating to this
         agreement.

         R&R advances the Company cash from time to time. As of March 31, 2004,
         the Company owed R&R $502,857 related to these advances. The Company
         has accrued interest on these advances at a rate of 10% per annum.
         Accrued interest at March 31, 2004 related to these advances totaled
         $48,610.

         In September 2003, R&R advanced the Company an additional amount of
         $170,000 at the rate of 10% per annum. These funds were specifically to
         provide the Company with additional financing with regard to the
         InnoFood transaction. (See Note 8) Accrued interest at March 31, 2004
         related to this advance was $13,647.


                                       37
<PAGE>



                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004



         (b) The Company currently owes its Chief Executive Officer $154,500 in
         past due compensation. The Company is accruing salary to its CEO at an
         annual rate of $125,000.

         (c) The Company currently owes other current and former executives a
         total of $164,192 in past due compensation.


NOTE 5 - CONVERTIBLE NOTE PAYABLE

         In September 2003, the Company sold a $600,000, three-year, 8%
         convertible note payable (the "Convertible Note"), which is convertible
         into shares of the Company's common stock at the initial conversion
         price of $2.00 per share. This price is subject to adjustment should
         the Company issue shares of its common stock at a price less than $1.75
         per share. The Convertible Debenture was sold with detachable
         three-year warrants (the "Debenture Warrants") to purchase 90,000
         shares of the Company's common stock at $2.88 per share. The warrant
         exercise price is also subject to adjustment based on sales of the
         Company's common stock below the current fair market value on the
         contract date.

         The Company capitalized $83,500 of debt issues costs that is being
         amortized over the life of the Convertible Note. During the year ended
         March 31, 2004, the Company amortized $15,618 relating to debt issue
         costs.

         The fair value of these warrants totaling $169,630 was computed using
         the Black-Scholes model under the following assumptions: (1) expected
         life of 3 years; (2) volatility of 104%, (3) risk free interest of
         4.39% and (4) dividend rate of $0%. In addition, since this debt is
         convertible into equity at the option of the note holder at beneficial
         conversion rates, an embedded beneficial conversion feature was
         recorded as a debt discount and amortized using the effective interest
         method over the life of the debt in accordance with Emerging Issues
         Task Force No. 00-27, "Application of Issue No. 98-5 to Certain
         Convertible Instruments." Since the intrinsic value of the beneficial
         conversion feature and relative fair value of the warrants exceeds the
         proceeds of the convertible debt, the amount of the discount assigned
         to the beneficial conversion feature and warrants is limited to the
         amount of the net proceeds of the convertible debt. Therefore, the
         Company recorded a discount of $516,500 (consisting of relative fair
         value of the warrants of $169,630 and beneficial conversion features of
         $346,870), the net proceeds received by the Company after the debt
         discount of $83,500. For the year ended March 31, 2004, the Company
         recorded the amortization of discount in the amounts of $24,363 as
         interest expense using the effective interest method. Upon conversion
         of the debt, any unamortized debt issue costs will be charged to
         expense.

         The Company also entered into a registration rights agreement whereby
         the Company agreed to file a valid registration statement with the
         Securities and Exchange Commission to register the shares of common
         stock underlying the Convertible Debentures and Debenture Warrants.


                                       38
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         Pursuant to EITF 00-19, "Accounting for Derivative Financial
         Instruments Indexed to, and Potentially Settled in, a Company's Own
         Stock", approximately $169,630, the relative fair value of the
         warrants, has been recorded as a short-term liability until the Company
         has obtained an effective registration statement for these shares. If
         the Company does not file such an effective registration statement
         within 30 days of the closing date, or October 8, 2003, the Company is
         subject to penalties as follows: 1% of the principal amount of the
         funding for the first 30 day period in which the Company fails to file
         such registration statement, and 2% for each 30 day period thereafter.
         At March 31, 2004, the Company had not filed such a registration
         statement and accordingly is currently subject to a penalty of
         approximately $66,000.

         In addition, the Company is required to report a value of the warrant
         as a fair value and record the fluctuation to the fair value of the
         warrant liability to current operations. During the period from
         September 8, 2004 to March 31, 2004, the decrease of the relative fair
         value of the warrants approximated $87,259. The relative fair value of
         the warrants approximated $82,371 as of March 31, 2004.

         This convertible note payable is presented in the accompanying
         consolidated balance sheet as a current liability as the Company has
         not made required interest payment on this convertible note as it
         becomes due which is an event of default that give the holder the right
         to call the convertible debenture pursuant to the terms of the note
         agreement.

         Per the terms of the note agreement, in the event of default, the
         Company is subject to accrue interest at a default rate of 18% from the
         date of the default. In addition, the Company is obligated to remit
         125% of the outstanding note balance upon the acceleration of repayment
         by the holder. During the year ended March 31, 2004, Company accrued
         interest of approximately $56,877 at a default rate of 18% from the
         date of default and accrued $150,000 as interest expense representing
         the additional amount of 125% of the outstanding note balance.

         In January 2004, the Company issued 135,000 shares of its common stock
         to the note holder, who agreed not to exercise any or all of its rights
         or remedies upon default stated in the note agreement until April 30,
         2004. The Company had not cured the defaults upon the due date. In May
         2004, the Company entered into a Forbearance Agreement with this note
         holder. Under the terms of the agreement, the Company agreed to issue
         170,000 shares of its common stock to this note holder as forbearance
         fee in order for it not to exercise the rights and remedies upon
         default stated in the note agreement until the earlier of (1) September
         30, 2004 or (2) such date that further event of default stated in the
         note agreement and the forbearance agreement. The Company accrued
         $692,500 as interest expense related to these issuances during the year
         ended March 31, 2004.



                                       39
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


NOTE 6 - CONVERTIBLE PREFERRED STOCK

         In September 2003, the Company sold 1,000 shares of its 7.5%
         convertible preferred stock (the "Convertible Preferred Stock") for
         $1,000,000, less direct issuance costs of $115,000, which were netted
         against the proceeds of the offering. The Convertible Preferred Stock
         carries voting rights equivalent to the number of shares of common
         stock into which it can be converted, and has liquidation preference of
         $1,000 per share. The Convertible Preferred Stock is convertible into
         shares of the Company's common stock at the initial conversion price of
         $2.40 per share. This price is subject to change should the Company
         issue shares of its common stock at a price less than $1.75 per share.
         Included with the Convertible Preferred Stock were detachable
         three-year warrants to purchase 104,167 shares of the Company's common
         stock at the price of $2.88 per share (the "Preferred Warrants"). The
         warrant exercise price is also subject to adjustment based on sales of
         the Company's common stock below the current fair market value on the
         contract date.

         The fair value of these warrants totaling $181,849 was computed using
         the Black-Scholes model under the following assumptions: (1) expected
         life of 3 years; (2) volatility of 112%, (3) risk free interest of 4.1%
         and (4) dividend rate of $0%. In addition, since this convertible
         preferred stock is convertible into equity at the option of the
         stockholder at beneficial conversion rates, an embedded beneficial
         conversion feature was recorded as a discount to additional paid in
         capital in accordance with Emerging Issues Task Force No. 00-27,
         "Application of Issue No. 98-5 to Certain Convertible Instruments."
         Since the intrinsic value of the beneficial conversion feature and
         relative fair value of the warrants exceeds the proceeds of the
         convertible debt, the amount of the discount assigned to the beneficial
         conversion feature and warrants is limited to the amount of the
         proceeds of the convertible preferred stock. The discount was recorded
         as a preferred stock dividend at the date of issuance. The Company
         recognized $885,000 of preferred dividends related to the discount.

         Pursuant to EITF 00-19, "Accounting for Derivative Financial
         Instruments Indexed to, and Potentially Settled in, a Company's Own
         Stock", approximately $181,849, the relative fair value of the
         warrants, has been recorded as a short-term liability until the Company
         has obtained an effective registration statement for these shares.

         If the Company does not file such an effective registration statement
         within 30 days of the closing date, or October 25, 2003, the Company is
         subject to penalties as follows: 1% of the value of the shares and the
         warrants paid by the purchaser for the first 30 day period in which the
         Company fails to file such registration statement, and 2% for each 30
         day period thereafter. At March 31, 2004, the Company had not filed
         such a registration statement and accordingly is currently subject to a
         penalty of $110,000.

         In addition, the Company is required to report a value of the warrant
         as a fair value and record the fluctuation to the fair value of the
         warrant liability to current operations. During the period from
         September 25, 2004 to March 31, 2004, the decrease of the relative fair
         value of the warrants approximated $122,082. The relative fair value of
         the warrants approximated $59,767 as of March 31, 2004.

         As of March 31, 2004, the Company has not declared any preferred
         dividends and there was $37,500 of dividends in arrears related to the
         1,000 share of convertible preferred stock.


                                       40
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         Pursuant to the Amended and Restated Articles of Incorporation, the
         Company is authorized to issue up to 5,000,000 shares of preferred
         stock. The Company has designated the issuance of a series of Preferred
         Stock to be called the "7.5% Convertible Preferred Stock." The total
         number of shares of Convertible Preferred Stock that the Company shall
         have the authority to issue is 1,000. Each share of the Convertible
         Preferred Stock has a par value of $0.001 per share. The holder of each
         share of the Convertible Preferred Stock shall be entitled to the
         number of votes equal to the number of shares of common stock into
         which such share of Convertible Preferred Stock could be converted for
         purposes of determining the shares entitled to vote at any regular,
         annual or special meeting of shareholders of the Company.


NOTE 7 - STOCK OPTIONS AND WARRANTS

         Stock Options
         -------------

         In 2002, the Company adopted a Stock Option Plan (the "Plan") initially
         reserving an aggregate of 1,250,000 shares of the Company's common
         stock (the "Available Shares") for issuance pursuant to the exercise of
         stock options, which may be granted to employees and consultants to the
         Company. The Plan options were subsequently increased to 2,000,000
         shares. The Company is in the process of amending the stock option plan
         to increase the number of shares authorized to be issued.

         The Plan provides for the granting at the discretion of the Board of
         Directors of both qualified incentive stock options and non-qualified
         stock options. Consultants may receive only non-qualified stock
         options. The maximum term of the stock options are three to five years
         and generally vest proportionately throughout the term of the option.

         Transactions under the Plans during the years ended March 31, 2003 and
         2004 are summarized as follows:

         The following table summarizes the options outstanding:

                                                                    Weighted
                                                  Stock             Average
                                                 Option            Exercise
                                                  Plan               Price
                                             --------------    ---------------


          Balance, March 31, 2002                  974,000     $       1.03
              Granted                              825,000     $       1.45
              Exercised                           (574,000)    $       1.00
              Canceled                             (75,000)    $       1.10
                                            --------------
          Balance, March 31, 2003                1,150,000     $       1.22
              Granted                            1,200,000     $       2.00
              Exercised                                  -     $         -
              Canceled                                   -     $         -
                                            --------------
          Balance, March 31, 2004                2,350,000     $       1.62
                                            ==============

          Exercisable at March 31, 2004          1,950,000     $       1.68
                                            ==============


                                       41
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         The weighted average remaining contractual life of options outstanding
         issued under the Plan is 5.01 years at March 31, 2004. The exercise
         price for the options outstanding under the Plan at March 31, 2004
         ranged from $1.00 to $2.00.

         For options granted during the year ended March 31, 2004 where the
         exercise price was greater than the stock price at the date of the
         grant, the weighted-average fair value of such options was $0.99 and
         the weighted-average exercise price of such options was $2.00. No
         options were granted during the year ended March 31, 2004 where the
         exercise price was equal to or less than the stock price at the date of
         grant. In addition to the 1,200,000 options granted by the Company
         during the year ended March 31, 2004, the Company's majority
         stockholder also granted an employee an option to purchase 1,000,000 of
         its shares at an exercise price of $2.00. The pro forma expense related
         to these 1,000,000 options is included in the pro forma disclosure in
         Footnote No. 1.

         The Black-Scholes option valuation model was developed for use in
         estimating the fair value of traded options which have no vesting
         restrictions and are fully transferable. In addition, option valuation
         models require the input of highly subjective assumptions including the
         expected stock price volatility. Because the Company's employee stock
         options have characteristics significantly different from those of
         traded options, and because changes in the subjective input assumptions
         can materially affect the fair value estimate, in management's opinion,
         the existing models do not necessarily provide a reliable single
         measure of the fair value of employee stock options.

         Warrants
         --------

         The Company has issued warrants in connection with the issuance of a
         convertible debenture and convertible preferred stock. The following
         table summarizes the warrants outstanding:

                                                                    WEIGHTED-
                                                                     AVERAGE
                                                                    EXERCISE
                                                 WARRANTS             PRICE

          Balance, March 31, 2003                         -      $        -
              Granted                               194,167      $      2.89
                                              --------------
          Balance, March 31, 2004                   194,167      $      2.89
                                              ==============

          Exercisable at March 31, 2004             194,167      $      2.89
                                              ==============



                                       42
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         The fair value for these warrants was estimated at the date of grant
         using a Black-Scholes option pricing model with the following
         weighted-average assumptions: risk-free interest rate of 4.23%;
         dividend yields of 0%; volatility factors of the expected market price
         of the Company's common stock ranging from 110% to 180%; and a weighted
         average expected life 1 to 3 years.

         The weighted average remaining contractual life of warrants outstanding
         is 2.46 years at March 31, 2004. The exercise price for the warrants
         outstanding at March 31, 2004 ranged from $2.88 to $2.90.


NOTE 8 - IMPAIRMENT EXPENSE

         On July 28, 2003, the Company entered into a definitive agreement (the
         "InnoFood Agreement") to acquire InnoFood, Inc. ("InnoFood"), owner of
         certain rights to a proprietary food processing technology developed by
         Modofood S.P.A. of Brescia, Italy. The agreement provided the Company
         exclusive distribution rights (through the acquisition of InnoFood) of
         Modofood's proprietary food sterilization and preservation technology
         for North America, Central America, South America and Japan, as well as
         the exclusive rights to negotiate on behalf of Modofood for Southeast
         Asia, including Taiwan, China and Indonesia.

         Under the terms of the agreement, InnoFood shareholders would receive
         one share of the Company's common stock and one warrant to purchase one
         share of the Company's common stock for every twelve (12) shares of
         InnoFood common stock. InnoFood shareholders were also to receive one
         InnoFood preferred share for every 1,200 InnoFood common shares. The
         agreement called for the Company to infuse $5 million of working
         capital prior to December 31, 2003.

         Prior to December 31, 2003, the Company has advanced InnoFood the sum
         of $2,220,000.

         On October 17, 2003 the Company entered into a Letter of Understanding
         ("LOU") with InnoFood to restructure the relationship between the
         Company and InnoFood. The Company believed that InnoFood may have
         misled the Company's management regarding certain material matters. As
         a result, the definitive agreements were never prepared and parties did
         not finalize the matters referenced in the LOU.

         On January 8, 2004, InnoFood sent the Company a letter explaining that
         InnoFood was terminating the original InnoFood agreement and the
         October 17, 2003 LOU. InnoFood claimed that the Company breached both
         the original Agreement and the LOU by failing to provide the funding
         provided for under those agreements. With the letter of termination,
         InnoFood delivered a signed Promissory Note agreeing to pay back the
         $2,160,000 (net of interest of $60,000 InnoFood charged to the Company
         for non-payments). The Promissory Note accrues interest at 10% and is
         due and payable on or before January 15, 2009. As of June 15, 2004, the
         Company has not yet accepted the terms of this promissory note and is
         still in negotiation with InnoFood regarding the purchase.



                                       43
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         The Company believes that InnoFood breached not only the original
         InnoFood Agreement but also the LOU. The Company intends to vigorously
         pursue InnoFood and all other responsible parties, but has not
         determined whether it will file suit against InnoFood and any other
         parties. The Company may also consider pursuing legal action against
         Modofood S.P.A.; if it is unable to resolve these matters informally
         through negotiations now taking place. In the meantime, the Company is
         attempting to resolve this dispute without court intervention.

         Since the Company believes that InnoFood breached the original
         agreement and the LOU, it did not fund the additional $2,780,000 which
         was to be used by InnoFood as working capital to expand its operations
         to be able to generate an operating profit. Due to the lack of funding
         received by InnoFood by the Company or another party, the Company
         believes that InnoFood's current financial condition is not sufficient
         to be able to repay the Promissory Note InnoFood issued to the Company.
         As a result, the Company has written off the entire amount of the
         acquisition deposit paid to InnoFood in the amount of $2,220,000.

         As more fully disclosed in Note 1, the Company also recorded an
         impairment charge of $111,522 related to the writedown of one of its
         patents.


NOTE 9 - INCOME TAXES

         Deferred income taxes reflect the net tax effects of temporary
         differences between the carrying amounts of assets and liabilities for
         financial statement purposes and the amounts used for income tax
         purposes. Significant components of the Company's deferred tax
         liabilities and assets as of March 31, 2004 are as follows:

         Deferred tax assets:

            Federal net operating loss carryforwards              $   1,855,000
            State net operating loss carryforwards                      215,000
            Equity instruments issued for compensation/services         254,000
            Accrued compensation                                        211,000
            Impairment of acquisition deposits and patent costs         933,000
                                                                  --------------
                                                                      3,468,000

         Total deferred tax assets
            Less valuation allowance                                 (3,468,000)
                                                                  --------------

                                                                  $          --
                                                                  =============

         During the year ended March 31, 2004, the valuation allowance increased
         by $2,193,000.


                                       44
<PAGE>



                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         At March 31, 2004, the Company had federal and state net operating loss
         ("NOL") carryforwards of approximately $5,659,000 and $2,430,000,
         respectively, which include federal and state NOL in the amount of
         approximately $4,200,000 and $1,662,000 respectively, from Biogentec,
         Inc., prior to the effective date of the reverse merger on July 2,
         2003.   Federal NOLs could, if unused, expire in varying amounts in
         the years 2020 through 2024. State NOLs, if unused, could expire in
         varying amounts from 2005 through 2009.

         The reconciliation of the effective income tax rate to the federal
         statutory rate for the years ended March 31, 2004 and 2003 is as
         follows:

                                                    2003               2003
                                                -----------        -----------
          Federal income tax rate                  (34.0%)           (34.0%)
          State tax, net of federal benefit         (6.0%)            (6.0%)
          Equity instruments issued for
             Compensation/services                   4.4%              -
          Accrued compensation                       3.7%              -
          Impairment expense                        16.4%              -
          Increase in valuation allowance           15.5%             40.0%
                                                -----------        -----------
          Effective income tax rate                  0.0%              0.0%
                                                ===========        ===========


         The full realization of the tax benefit associated with the
         carryforward depends predominantly upon the Company's ability to
         generate taxable income during the carryforward period. The allowable
         amount of the net operating loss carryforwards and the year
         availability are subject to change of ownership limitations under
         Internal Revenue Code Section 382.


NOTE 10 - COMMITMENTS AND CONTINGENCIES

         Litigation
         ----------

         As of March 31, 2003, Biogentec Incorporated, which is as of the date
         of this report, the Company's wholly owned subsidiary, vacated
         previously occupied office space and is in a dispute with the prior
         landlord. The landlord has filed suit in the County of Orange, Superior
         Court of California, Case #03CC02904. The Company accrued a liability
         of approximately $60,000 related to this lawsuit.

         In the ordinary course of business, the Company is generally subject to
         claims, complaints, and legal actions. At March 31, 2004, management
         believes that the Company is not a party to any action which would have
         a material impact on its financial condition, operations, or cash
         flows.

         Leases
         ------

         The Company currently leases its corporate office under an operating
         lease that expires in March 2006. The Company has paid a security
         deposit of $40,000 per the terms of the lease agreement.

         Rent expense for the years ended March 31, 2004 and 2003 and for the
         period from November 22, 2000 (inception)to March 31, 2004, was $
         125,680, $112,106, and $283,259, respectively.



                                       45
<PAGE>


                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004


         Future minimum lease payments applicable to non-cancelable operating
         leases as of March 31, 2004, are as follows:

                                                                  Operating
                                                                   Leases
          Year ending March 31,
               2005                                           $       124,374
               2006                                                   124,374
                                                              ---------------

          Net Minimum Lease Payments                          $       247,748
                                                              ===============


         Common Shares Issued For Loan Collateral
         ----------------------------------------

         During July 2003, the Company was negotiating with a lender in Germany
         for a loan in the amount of approximately $2,400,000. On July 31, 2003,
         the Company issued 3,000,000 shares of its restricted common stock as
         collateral for this loan. This transaction was never completed, there
         was no consideration to serve as basis for a transaction, and the
         Company is in the process of attempting to cancel the share
         certificate. These shares are shown as issued as of March 31, 2004, but
         not outstanding. The share certificates have not yet been returned by
         the prospective lender. If the certificates are not returned, the
         Company will take a charge to earnings for the value of these shares.

NOTE 11 - RESTATEMENT OF PRIOR YEAR FINANCIAL STATEMENTS

         As discussed in Note 2, the Company entered into agreements with GP LLC
         to purchase certain patents and other assets. The Company previously
         had valued the patents based on the present value of the minimum
         contractual obligations using a 6% discount rate. Per the December 19,
         2002 agreement, the Company issued to GP LLC 2,000,000 shares of the
         Company's common stock in exchange for the minimum contractual
         payments. At the time the Company valued the transaction based on the
         deemed current value of the Company's common stock, which resulted in
         the Company increasing the carrying value of the patents by $1,658,378.
         The Company's stock was not publicly traded so the Company valued its
         stock at $2.00 per share which was the most recent price that the
         Company had sold shares for cash. After this increase in the value of
         patents, the patents carrying value was $3,905,832. At March 31, 2003,
         the patents were appraised at $3,850,000 which resulted in the Company
         writing down the value of the patents by $55,832.

         The Company has restated its previously issued consolidated financial
         statements to reflect using a discount rate of 15.5% rather than 6% to
         value the minimum contractual obligations and to value the 2,000,000
         shares of common stock issued in the December 19, 2002 transaction at
         the carrying value of the contractual obligation that was exchanged for
         the shares rather than at the deemed current value of the shares at the
         date of issuance.


                                       46
<PAGE>

                          COBALIS CORP. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
           FOR THE YEARS ENDED MARCH 31, 2004 AND 2003 AND THE PERIOD
              FROM NOVEMBER 21, 2000 (INCEPTION) TO MARCH 31, 2004



         In addition, the Company did not amortize the value of its patents. The
         accompanying consolidated financial statements have been restated to
         reflect the amortization of the Company's patents over the estimated
         useful life of the patents using the straight line method. Amortization
         expense for the years ended March 31, 2001, 2002 and 2003 was $20,458,
         $84,690 and $87,161, respectively.

         The effects of the restatement are as follows:
<TABLE>
<CAPTION>
                                                           AS PREVIOUSLY
                                                              FILED          AS RESTATED
              <S>                                              <C>               <C>

         March 31, 2001
              Patents                                    $     2,222,744  $      1,100,756
              Accumulated amortization of patents        $             -  $         20,458
              Contract payable                           $     2,206,422  $      1,092,530
              Total Stockholders' equity                 $        76,117  $         47,565
              Net loss                                   $     (194,864)  $      (223,416)


         March 31, 2002
              Patents                                    $     2,246,005  $      1,124,017
              Accumulated amortization of patents        $             -  $        105,148
              Contract payable                           $     2,259,533  $      1,176,802
              Total Stockholders' deficit                $     (260,911)  $      (405,315)
              Net loss                                   $   (1,028,397)  $    (1,144,249)


         March 31, 2003
              Patents                                    $     3,850,000  $      1,125,466
              Accumulated amortization of patents        $             -  $        192,309
              Total Stockholders' equity                 $     3,418,865  $        502,022
              Net loss                                   $   (2,087,652)  $    (2,148,008)
</TABLE>


NOTE 11 - SUBSEQUENT EVENTS (UNAUDITED)

         On May 28, 2004, the Company entered into a Forbearance Agreement with
         Gryphon Master Fund L.P., the holder of the $600,000 convertible note
         payable and convertible preferred stock. The Company is in default on
         certain provisions of the Operative Documents in that it has failed to
         register the shares underlying the conversion of the convertible note
         payable and preferred stock and has failed to have the registration
         statement declared effective by the SEC, and has not made its required
         interest payments upon due. These events of default give Gryphon the
         right to immediately enforce all the right and remedies set forth in
         the Operative Documents. In consideration for Gryphon not exercising
         any of its rights under the Operative Documents until September 30,
         2004, the Company has agreed to issue to Gryphon a total of 170,000
         shares of the Company's common stock. Since these defaults occurred
         prior to March 31, 2004, the Company has recorded $314,500, the fair
         value of the 170,000 shares, as an accrued expense.

         The Company changed its corporate name to Cobalis Corp. with the filing
         of a Certificate of Amendment to our corporate articles in Nevada on
         July 6, 2004.

         In July 2004, the Company was granted a Patent in Austrailia #771.728
         which is equivalent to the U.S. patent #6.255.294 "Cyanvcobalamin
         Treatment in Allergic Disease."


                                       47
<PAGE>


ITEM 8.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS.
-------------------------------------------------------

There have been no changes in or disagreements with our accountants since our
formation required to be disclosed pursuant to Item 304 of Regulation S-B.

ITEM 8A. CONTROLS AND PROCEDURES.

(a) Evaluation of disclosure controls and procedures. We maintain controls and
procedures designed to ensure that information required to be disclosed in the
reports that we file or submit under the Securities Exchange Act of 1934 is
recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the Securities and Exchange Commission. Based upon
their evaluation of those controls and procedures performed within 90 days of
the filing date of this report, our chief executive officer and the principal
financial officer concluded that our disclosure controls and procedures were
adequate.

(b) Changes in internal controls. There were no significant changes in our
internal controls or in other factors that could significantly affect these
controls subsequent to the date of the evaluation of those controls by the chief
executive officer and principal financial officer.

                                    PART III

ITEM 9.  DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS.

EXECUTIVE OFFICERS AND DIRECTORS. Our directors and principal executive
officers are as specified on the following table:


===================== ========= ===============================================
NAME                    AGE     POSITION
--------------------- --------- -----------------------------------------------
Chaslav Radovich         44     President, Secretary, Treasurer and a Director
--------------------- --------- -----------------------------------------------
Radul Radovich           81     Director
--------------------- --------- -----------------------------------------------
Ernest Armstrong         44     Vice President of Business Development
--------------------- --------- -----------------------------------------------
Kevin Prendiville        50     Director
===================== ========= ===============================================

RADUL "RUDY" RADOVICH, CHAIRMAN OF THE BOARD OF DIRECTORS. Mr. Radovich, age 81,
has been a Senior Project Manager and Project Head for several multi-billion
dollar projects with Ciba-Geigy (Novartis), British Petroleum, Parsons, Narmco,
Page Engineering and others. His leadership and focus on deliverable results
enabled Mr. Radovich to complete each project as scoped, on time and within
budget, driving customer satisfaction and profitability in line with
projections. His extensive and diverse experience equipped him to provide
consulting services to several Fortune 100 corporations. Radovich has been
Chairman of R & R Holdings, Inc., a private investment banking company, for over
15 years. He earned an MSME at University of Belgrade, Yugoslavia. Mr. Radul
Radovich is not an officer or director of any other reporting company.

CHASLAV "CHAS" RADOVICH, PRESIDENT, CHIEF EXECUTIVE OFFICER AND A DIRECTOR. Mr.
Radovich, age 44, was Founder and CEO of Best Electronics, Inc., from 1986
through 1992. Best Electronics was a wholesaler-distributor of computer memory
and peripheral products for companies including Intel, NEC, Toshiba, Motorola
and Texas Instruments. From inception, Best Electronics, Inc. was profitable and
Mr. Radovich grew earnings by more than 24% per year, while strategically
expanding the staff to 25. Since 1992, he has been an independent investor and
investment banker with R & R Holdings, Inc. Over the last ten years, Mr.
Radovich has raised well over $100 million for private and public companies and
played an instrumental role in taking many of them public, including Healthstar,
Pharmaprint, Logon America and AimSmart. Mr. Radovich is not an officer or
director of any other reporting company.


                                       48
<PAGE>

ERNEST ARMSTRONG, VICE PRESIDENT-BUSINESS DEVELOPMENT. Mr. Armstrong, age 44, as
CEO of Gene Pharmaceuticals, LLC, has overseen clinical research on allergic
rhinitis products and out-licensed medical technology for us. From 1991 through
1996, Mr. Armstrong was Founder and President of Broncorp, Inc., a
research-based pharmaceutical company focused on drug-delivery technologies and
on developing treatments for asthma and allergy. He was an Associate Professor
of International Business at Dai-Ichi Economics College, Fukuoka, Japan
1998-1991. Armstrong speaks seven languages and previously lived in Canada,
France, Guatemala, Italy, Japan and Switzerland. His education includes:
BA-International Marketing and core courses for BS in Biology, Humboldt State
University, Arcata, California; BA-French, University of Aix-en-Provence,
France; MBA-San Francisco State University. Mr. Armstrong is not an officer or
director of any other reporting company.

ALSO ON OUR BOARD OF DIRECTORS:

KEVIN J. PRENDIVILLE, M.D., F.A.C.S. Dr. Prendiville is a Diplomate of the
American Board of Ophthalmology and a Fellow of the American College of
Surgeons. Since 1986, he has operated a thriving ophthalmology practice in
Cottonwood and Sedona, Arizona, specializing in small incision cataract surgery,
cosmetic and functional eyelid surgery as well as excimer laser vision
correction. Dr. Prendiville also serves as Medical Director for the
Cottonwood/Verde Valley Eye Surgery Center and, since 1989, has held numerous
medical leadership positions at Verde Valley Medical Center in Cottonwood. Dr.
Prendiville is not an officer or director of any other reporting company.

Chaslav Radovich is the son of Radul Radovich. There are no orders, judgments,
or decrees of any governmental agency or administrator, or of any court of
competent jurisdiction, revoking or suspending for cause any license, permit or
other authority to engage in the securities business or in the sale of a
particular security or temporarily or permanently restraining any of our
officers or directors from engaging in or continuing any conduct, practice or
employment in connection with the purchase or sale of securities, or convicting
such person of any felony or misdemeanor involving a security, or any aspect of
the securities business or of theft or of any felony. Nor are any of the
officers or directors of any corporation or entity affiliated with us so
enjoined.

OUR MEDICAL ADVISORY BOARD. Our Medical Advisory Board consists of nine doctors,
preeminent in the fields of allergy and immunology, as well as an attorney with
extensive education in immunology, biochemistry and intellectual property law.
These physicians and medical research scientists are associated with top
healthcare institutions throughout the country and have long term experience in
allergy and immunology as well as managing and conducting clinical trials.
Several of the advisory board members have previously contributed their
scientific and medical expertise to the research and development of the
company's foundation product, as well as products in our development pipeline.

The members of this advisory board are:

JAMES M. BRODSKY, RPH, ND, HMD, CHIEF RESEARCHER. Dr. Brodsky is a facilitating
professor at the University of Southern California School of Pharmacy. He has
been on the teaching staff at the University of the Pacific Pharmacology
Department and at Santa Ana College he taught Pharmacy Terminology. He has
published numerous articles on natural medicine and is a recognized speaker on
Natural Medicine. Dr. Brodsky has been the owner/pharmacist of Villa Park
Pharmacy for over 25 years. Dr. Brodsky has been a member of the American
Pharmaceutical Association, the California Pharmaceutical Association, the
Orange County Pharmaceutical Association and the American Naturopathic Medical
Association.

LYNDON E. MANSFIELD, MD, PRINCIPAL INVESTIGATIVE PHYSICIAN. Dr. Mansfield, a key
medical advisor and the Principal Investigative Physician for BioGentec Inc.
since 1992, has conducted many allergy related clinical research studies for
major pharmaceutical companies and was instrumental in preparing and presenting
the prior trial results for PreHistin (TM)(TM)to the FDA. Education: Temple
University, Thomas Jefferson Medical University - Doctor of Medicine. Residency:
Pediatrics - Brooke Army Medical Center. Board Certifications: Pediatrics,
Allergy and Clinical Immunology, Diagnostic Laboratory Immunology/Clinical Lab,
Immunology. Professional Societies: Fellow, American Academy Allergy &
Immunology Allergy & Immunology, Fellow, American College of Allergists,
Association of Medical Laboratory Immunologists.


                                       49
<PAGE>


ALVIN J. AUBRY, MD. EDUCATION: Tulane University School of Public Health -
Master of Public Health, Tulane University School of Medicine - Doctor of
Medicine, Straight Pediatrics at Brooke Army Medical Center - Internship.
Residency: Pediatrics - Madigan Army Medical Center. Fellowship: Allergy &
Immunology, Fitzsimmons Army Medical Center. Board Certifications: American
Board of Pediatrics, American Board of Allergy & Immunology.

RICHARD E. DANZIGER M.D., PH.D. Education: George Washington University - M.D.,
University of Alberta - Ph.D., Dartmouth College - BA. Board Certifications:
American Board of Pediatrics - Diplomate, American Board of Allergy & Immunology
- Diplomate. Publications: Wagner, C.J.; Danziger, R.E. and Nelson, H.S.
"Relation Between Positive Small Air Ions, Weather Fronts and Pulmonary Function
in Patients with Bronchial Asthma. Annals of Allergy 51 (4): 430-435. 1983.
Fortner, B.R.; Danziger, R.E.; Rabinowitz, P.S. and Nelson, H.S. The effect of
ascorbic acid on cutaneous and nasal response to histamine and allergen. J.
Allergy Clinical Immunology. (69) 484--488. 1982. Numerous additional
publications and presentations.

STANLEY GOLDSTEIN, M.D. Education: Yeshiva University - B.A., New York Medical
College - M.D. Internship: Long Island Jewish Hillside Medical Center -
Pediatric Internship. Residency: Long Island Jewish Hillside Medical Center -
Pediatric Residency, Long Island Jewish Hillside Medical Center - Senior
Resident in Pediatrics. Faculty Appointments: State University of N.Y. -
Assistant Clinical Instructor, Long Island Jewish Hillside Medical Center -
Director of Allergy Clinic, The Long Island College Hospital - Research
Coordinator and Attending Department of Allergy & Immunology. Board
Certifications: American Board of Pediatrics, American Board of Allergy &
Immunology, and American Board of Pediatric Pulmonary. Publications: Goldstein,
S., Rose, JO., Sutton, PL., Koup, JR., Jusko, WJ., and Middleton, E., Jr.: The
Pharmacokinetics of Prednisone and Its Metabolite Prenisolone in Pregnant
Asthmatics, J. Allergy Clinical Immunology Vol. 63, No. 3, March 1979, p. 219.
Goldstein, S., Mueller, U., Wypysch, J., Reisman, R., and Arbesdman, C.:
Treatment of Ragweed Sensitive Patients with Ragweed Fraction A conjugated to
D-glutamic Acid: D-Lysine (FA:DGL). J. Allergy Clinical Immunology, Vol. 65, No.
3, March 1980. Numerous additional publications.


                                       50
<PAGE>


LEWIS JOSEPH KANTER, M.D. Education: University of California - B.S. Biological
Sciences, Georgetown University School of Medicine - M.D. Internship: Pediatrics
- National Naval Medical Center. Residency: Pediatrics - National Naval Medical
Center. Board Certifications: American Board of Pediatrics - Board Certified,
America Board of Allergy and Immunology (A Conjoint Board of the American Board
of Pediatrics and American Board of Internal Medicine) - Board Certified.
Faculty Appointments: Uniformed Services University of Health Sciences,
Assistant Professor of Pediatrics and Assistant Professor in Internal Medicine,
University of California at Los Angeles School of Medicine, Clinical faculty.
Publications: Nedocromil in the Outpatient Management of Asthma, Arch Fam Med
1995' 4:835-842. Inhaled Fluticasone Propionate in the Treatment of Asthma,
Advances in Therapy Jan/Feb 1997, Vol. 14. No. 1. Inhaled Corticosteriods for
Asthma Therapy, Epitomes-Allergy & Immunology, Western Journal of Medicine Nov.
1997, Vol. 167, No. 5; 343-346. Numerous additional publications and
presentations.

ANITA M. KIRKPATRICK, PH.D. Education: University of San Diego School of Law -
Juris Doctor Degree, Massachusetts Institute of Technology Sloan School of
Management - Master's Degree in Management of Technology, University of New
Mexico School of Medicine - Ph.D. in the Medical Sciences (Biochemistry), New
Mexico Highlands University M.S. in Chemistry, Mount St. Mary's College/San
Diego State College - B.S. in Chemistry. Certification and Licensure: California
State License in Clinical Chemistry, Certified Specialist in Immunology,
American Society of Clinical Pathologists. Professional Societies: American
Association for Clinical Chemistry, American Chemical Society; San Diego
Section, American Society of Clinical Pathology, American Society for
Microbiology, American Intellectual Property Law Association, California
Association for Medical Laboratory Technology, San Diego County Bar Association,
San Diego Intellectual Property Law Association, Licensing Executives Society.
Joseph T. Morgan, M.D. Education: University of Colorado School of Medicine,
M.D. Internship: Good Samaritan Hospital - General Rotating Internship,
Pediatric Residency: St. Joseph's Hospital, University of Colorado Medical
Center, University of Colorado Medical Center - Chief Resident in Pediatrics.
Board Certification: The American Board of Pediatrics.

MICHAEL J. NOONAN, M.D. Education: University of Nebraska - B.S. Pre-Medicine,
University of Nebraska College of Medicine - M.D., University of Oregon.
Internship: Emanuel Hospital - Rotating Internship. Residency: University of
Oregon Medical Center - Pediatric, Fellowship: National Jewish Hospital -
Allergy & Immunology, Oregon Health Sciences University - Allergy Immunology
Fellowship. Board Certifications: American Board of Pediatrics, American Board
of Allergy & Immunology. Faculty Appointments: Department of Pediatrics, Oregon
Health Sciences University - Associate Clinical Professor. Publications: Asthma,
Allergy & Immunology, Vol. 10, No 4 1996. Noonan MJ, Chervinsky P, Wolfe J,
Liddles R, Kellerman DJ, Crescenzi KL; Does Related Response to Inhaled
Flutisone Propionate in Patients with Methacholine-Induced Bronchial Hyper
responsiveness: A Double-Blind, Placebo-Controlled Study. Journal of Asthma Vo1.
35(2), 1998. Numerous additional Publications and Research Interests.

CHARLES JAY SIEGEL, M.D. Education: University of Wisconsin-Madison, Medical
College of Wisconsin - M.D. Internship: Children's Mercy Hospital - Pediatrics.
Residency: Children's Mercy Hospital - Pediatrics. Fellowship: Children's Mercy
Hospital, University of Kansas Medical Center. Board Certifications: National
Board of Medical Examiners, American Board of Pediatrics, and American Board of
Allergy & Immunology. Honors: Board of Regents, American College of Allergy,
Asthma, & Immunology - 1993-1995, Executive Committee American College of
Allergy, Asthma, & Immunology - 1994-1995, Chairman CME Committee of The
American College of Allergy Asthma & Immunology - 1997-2001, Chairman
Re-certification Committee of The American College of Allergy Asthma &
Immunology, Chairman Pharmaceutical Symposia Committee American College of
Allergy Asthma & Immunology, and Program committee 1997-2000 The American
College of Allergy Asthma & Immunology. Publications: Author of numerous
articles.


                                       51
<PAGE>


There are no orders, judgments, or decrees of any governmental agency or
administrator, or of any court of competent jurisdiction, revoking or suspending
for cause any license, permit or other authority to engage in the securities
business or in the sale of a particular security or temporarily or permanently
restraining any of our officers or directors from engaging in or continuing any
conduct, practice or employment in connection with the purchase or sale of
securities, or convicting such person of any felony or misdemeanor involving a
security, or any aspect of the securities business or of theft or of any felony,
nor are any of the officers or directors of any corporation or entity affiliated
with us so enjoined.

Our directors will serve until the next annual meeting of stockholders. Our
executive officers are appointed by our Board of Directors and serve at the
discretion of the Board of Directors.

AUDIT COMMITTEE AND FINANCIAL EXPERT. Because our Board of Director currently
consists of only one member and we do not have the resources to expand our
management at this time, we do not have an audit committee, nor do we have a
financial expert on our Board of Directors as that term is defined by Item
401(e)2.

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE. Section 16(a) of the
Securities Act of 1934 requires our directors, executive officers, and any
persons who own more than 10% of a registered class of our equity securities, to
file reports of ownership and changes in ownership with the Securities and
Exchange Commission. SEC regulation requires executive officers, directors and
greater than 10% stockholders to furnish us with copies of all Section 16(a)
forms they file. Based solely on our review of the copies of such forms received
by us, or written representations from certain reporting persons, we believe
that during the fiscal year ended March 31, 2004 our executive officers,
directors, and greater than 10% stockholders complied with all applicable filing
requirements.

CODE OF ETHICS. We have not adopted a code of ethics that applies to our
principal executive officer, principal financial officer, principal accounting
officer or controller, or persons performing similar functions. We are in the
process of preparing and adopting a code of ethics.

ITEM 10.  EXECUTIVE COMPENSATION
---------------------------------

Any compensation received by our officers, directors, and management personnel
will be determined from time to time by our Board of Directors. Our officers,
directors, and management personnel will be reimbursed for any out-of-pocket
expenses incurred on our behalf.

SUMMARY COMPENSATION TABLE. The table set forth below summarizes the annual and
long-term compensation for services in all capacities to us payable to our chief
executive officer and our other executive officers during the fiscal years
ending December 31, 2002 and March 31, 2004. During 2003, we changed our fiscal
year end from December 31 to March 31. Our Board of Directors may adopt an
incentive stock option plan for our executive officers which would result in
additional compensation.


                                       52
<PAGE>


<TABLE>
<CAPTION>
====================== ======= ==================================== =============================================== ================
                                       ANNUAL COMPENSATION                       LONG TERM COMPENSATION

---------------------- ------- ------------------------------------ ----------------------------------------------- ----------------
 NAME AND PRINCIPAL     YEAR   SALARY     BONUS     OTHER ANNUAL                 AWARDS                  PAYOUTS       ALL OTHER
      POSITION                    ($)       ($)   COMPENSATION ($)                                                    COMPENSATION
---------------------- ------- ---------- ------ ------------------ ---------------------------------- ------------ ----------------
                                                                     RESTRICTED        SECURITIES         LTIP
                                                                    STOCK AWARDS       UNDERLYING      PAYOUTS ($)
                                                                         ($)        OPTIONS/SARS (#)
---------------------- ------- ---------- ------ ------------------ -------------- ------------------- ------------ ----------------
<S>                      <C>       <C>      <C>         <C>              <C>              <C>             <C>              <C>
Chaslav Radovich -     2003     125,000    None         None            None              None            None            None
president, secretary
---------------------- ------- ---------- ------ ------------------ -------------- ------------------- ------------ ----------------
                       2004     125,000   None          None            None              None            None            None
---------------------- ------- ---------- ------ ------------------ -------------- ------------------- ------------ ----------------
Ernest Armstrong-      2003     100,000   None          None            None              None            None            None
vice president  of
business development
---------------------- ------- ---------- ------ ------------------ -------------- ------------------- ------------ ----------------
                       2004     100,000   None          None            None            None(1)           None            None
---------------------- ------- ---------- ------ ------------------ -------------- ------------------- ------------ ----------------
James Luce, former     2003     150,000   None          None            None              None            None            None
chief operating
officer, chief
marketing officer
---------------------- ------- ---------- ------ ------------------ -------------- ------------------- ------------ ----------------
                       2004     150,000   None          None            None              None            None            None
---------------------- ------- ---------- ------ ------------------ -------------- ------------------- ------------ ----------------

====================== ======= ========== ====== ================== ============== =================== ============ ================
</TABLE>
(1)In February 2004, we agreed to grant Mr. Ernest Armstrong 1,200,000 options
to purchase shares of our common stock. In addition, St. Petka Trust, our
majority shareholder, agreed to grant to Mr. Armstrong 1,000,000 options to
purchase shares of our common stock that it owns. These options have not yet
been transferred or issued to Mr. Armstrong.

COMPENSATION OF DIRECTORS. Our current directors who are also our employees
receive no extra compensation for their service on our board of directors.

COMPENSATION OF OFFICERS. As of July 14, 2004, our officers have received no
other compensation for their services provided to us, except as described in the
table above.

Employment Contracts. Our wholly-owned subsidiary, BioGentec, entered into an
employment agreement with our President (previously the Executive Vice
President) dated November 22, 2000, amended on December 31, 2001, which pays an
annual salary of up to $125,000 and certain bonuses. For the year ended March
31, 2004, we expensed $125,000 of salary for the President and as of March 31,
2004 we have a payable to the President totaling $154,500.

BioGentec has entered into an informal employment agreement with the Chief
Operating Officer ("COO") that pays an annual salary of $120,000 per year. The
agreement provides that the COO's base salary shall increase by increments of
$50,000 per year upon the achievements of certain milestones, including our
obtaining financing and achieving certain levels of revenues. In addition, the
agreement provides that the COO shall be eligible to receive bonuses tied to our
revenues.


                                       53
<PAGE>


As of March 31, 2004, we owed the COO approximately $75,625 pursuant to this
agreement. This amount is included in due to related parties in the accompanying
consolidated financial statements. Our COO recently left our service and is no
longer employed by us.

Mr. Armstrong has agreed to serve as our Vice President of Business Development
in conjunction with BioGentec's purchase of the patent underlying our principal
product (formerly known as "Immun-Eeze") in 2000. Mr. Armstrong receives a
salary of $100,000 annually, and, as the principal owner of Gene
Pharmaceuticals, LLC is entitled to certain royalties and other compensation. In
December 2002, the parties agreed to amend the original agreement to settle
unpaid minimum royalty through issuance of 2,000,000 shares of BioGentec's
common stock, plus royalties on future sales of products. In March 2004, we
agreed to further amend the original underlying agreement, including the royalty
provision in the underlying agreement, although the specific terms have not yet
been finalized. In February 2004, we agreed to grant Mr. Ernest Armstrong
1,200,000 options to purchase shares of our common stock. In addition, St. Petka
Trust, our majority shareholder, agreed to grant to Mr. Armstrong 1,000,000
options to purchase shares of our common stock that it owns. The exercise prices
of these options were above the market price of our common stock on the date of
the grant; therefore, no expense was recognized.


ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
------------------------------------------------------------------------

The following table sets forth certain information regarding the beneficial
ownership of our common stock as of June 16, 2004, by each person or entity
known by us to be the beneficial owner of more than 5% of the outstanding shares
of common stock, each of our directors and named executive officers, and all of
our directors and executive officers as a group. The percentages in the table
assume that the selling security holders will not sell any of their shares which
are being registered in this registration statement.
<TABLE>
<CAPTION>
=================== ======================================== ==================================== ===================
TITLE OF CLASS      NAME AND ADDRESS OF BENEFICIAL OWNER       AMOUNT AND NATURE OF BENEFICIAL     PERCENT OF CLASS
                                                                            OWNER
------------------- ---------------------------------------- ------------------------------------ -------------------
     <S>                          <C>                                        <C>                          <C>
Common Stock        Chaslav Radovich (1)                               414,101 shares                    1.5%
                    2445 McCabe Way, Suite 150                 President, Secretary, Treasurer
                    Irvine, CA, 92614                                   and Director
------------------- ---------------------------------------- ------------------------------------ -------------------
Common Stock        St. Petka Trust (2)                               12,198,166 shares                 50.1%
                    46 Calle Fresno
                    San Clemente, CA, 92672
------------------- ---------------------------------------- ------------------------------------ -------------------
Common Stock        Radul Radovich (2)                                12,198,166 shares                 50.1%
                    46 Calle Fresno                                       Director
                    San Clemente, CA, 92672
------------------- ---------------------------------------- ------------------------------------ -------------------
Common Stock        Silver Mountain Promotions (2)                    12,198,166 shares                 50.1%
                    6446 Silver Dawn Lane
                    Las Vegas, NV, 89118
------------------- ---------------------------------------- ------------------------------------ -------------------
Common Stock        R&R Holdings (2)                                  12,198,166 shares                 50.1%
                    46 Calle Fresno
                    San Clemente, CA, 92672
------------------- ---------------------------------------- ------------------------------------ -------------------
Common Stock        Ernest Armstrong (3)                              2,145,814 shares                   8.8%
                    2445 McCabe Way, Suite 150                     Vice President Business
                    Irvine, CA, 92614                                    Development
------------------- ---------------------------------------- ------------------------------------ -------------------
Common Stock        Gene Pharmaceuticals (3)                          2,020,000 shares                  10.0%
                    2445 McCabe Way, Suite 150
                    Irvine, CA, 2614
------------------- ---------------------------------------- ------------------------------------ -------------------
Common Stock        Kevin Prendiville (4)                              610,000 shares                    2.5%
                    1791 Franquers Ln                                     Director
                    Cottonwood, AZ, 86326
------------------- ---------------------------------------- ------------------------------------ -------------------
Common Stock        Officers and directors as a group
                                                                      15,380,581 shares                 63.0%
=================== ======================================== ==================================== ===================
</TABLE>


                                       54
<PAGE>

     (1)Chaslav Radovich owns 307,101 individually and is the custodian of the
     44,000 shares owned by Milena Radovich, his minor child.

     (2)Radul Radovich is one of the beneficiaries of the St. Petka Trust, which
     owns 11,750,000 shares. Radul Radovich and his spouse are the owners of R&R
     Holdings which holds 333 shares of our stock, and of Silver Mountain
     Promotions which holds 447,833 shares of our common stock.

     (3)Ernest Armstrong owns 125,814 individually and is the sole owner of Gene
     Pharmaceuticals, LLC, which owns 2,020,000 shares. Not shown above are
     options subject to an agreement between us, Mr. Armstrong and the St. Petka
     Trust. In February 2004, we agreed to grant Mr. Ernest Armstrong 1,200,000
     options to purchase shares of our common stock, though those options have
     not yet been granted. In addition, St. Petka Trust, our majority
     shareholder, agreed to transfer to Mr. Armstrong 1,000,000 options to
     purchase shares of our common stock that it owns.

     (4)Kevin Prendiville owns 12,500 shares directly and is one of the trustees
     of the Prendiville Revocable Trust, owner of 485,000 shares.

Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission and generally includes voting or investment
power with respect to securities. In accordance with Securities and Exchange
Commission rules, shares of our common stock which may be acquired upon exercise
of stock options or warrants which are currently exercisable or which become
exercisable within 60 days of the date of the table are deemed beneficially
owned by the optionees. Subject to community property laws, where applicable,
the persons or entities named in the table above have sole voting and investment
power with respect to all shares of our common stock indicated as beneficially
owned by them.

CHANGES IN CONTROL. Our management is not aware of any arrangements which may
result in "changes in control" as that term is defined by the provisions of Item
403(c) of Regulation S-B.

ITEM 12.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
---------------------------------------------------------

RELATED PARTY TRANSACTIONS.

CONSULTING CONTRACT. BioGentec has a consulting contract with R&R Holdings, Inc.
("R&R") whereby R&R would provide managerial consulting services to us at the
rate of $125,000 per year. As stated in the agreement, the rate increased to
$135,000 per year upon BioGentec's merger with our wholly-owned subsidiary. R&R
is also one of our shareholders. For the year ended March 31, 2004, we expensed
$135,000 under this contract. As of March 31, 2004, we have a payable to R&R
under the contact totaling $208,642 which is included in due to related parties.
Radul Radovich, one of our directors and his spouse are the owners of R&R
Holdings. Radul Radovich and his spouse are also beneficiaries of the St. Petka
Trust, which is our majority stockholder.

ADVANCES. During the year ended March 31, 2004, R&R advanced BioGentec
additional cash totaling $393,650 less repayments of $77,800. As of March 31,
2004, R&R has outstanding advances totaling $502,857. We have imputed interest
on the note at a rate of 10% per annum. Interest expense totaled $45,447 during
the year ended March 31, 2004. As of March 31, 2004, we have outstanding accrued
interest payable of $48,610 on these advances from R&R, which is included in due
to related parties.

In September 2003, R&R advanced us an additional amount of $170,000 at the rate
of 10% per annum. These funds were specifically to provide us with additional
financing with regard to the InnoFood transaction. (See Note 4 of the
consolidated financial statements) Interest expense in the amount of $13,647 was
accrued for the year ended March 31, 2004 relating to this advance and such
amount was included in due to related parties as of March 31, 2004.

EMPLOYMENT CONTRACTS. The President (previously the Executive Vice President)
entered into an employment agreement dated November 22, 2000, amended on
December 31, 2001, which pays an annual salary of up to $125,000 and certain
bonuses. We expensed $125,000 for year ended March 31, 2004. As of March 31,
2004, we have a payable to the President totaling $154,500 which is included in
due to related parties.

BioGentec has entered into an informal employment agreement with the Chief
Operating Officer ("COO") that pays an annual salary of $120,000 per year. The
agreement provides that the COO's base salary shall increase by increments of
$50,000 per year upon the achievements of certain milestones, including our
obtaining financing and achieving certain levels of revenues. In addition, the
agreement provides that the COO shall be eligible to receive bonuses tied to our
revenues.


                                       55
<PAGE>


We expensed $134,375 for the year ended March 31, 2004. During the three months
ended March 31, 2004, we paid $108,750 under this employment agreement. As of
March 31, 2004, we owed the COO approximately $75,625 pursuant to this
agreement. This amount is included in due to related parties in the accompanying
consolidated financial statements.

INTELLECTUAL PROPERTY AGREEMENT. In 2000 BioGentec purchased the patent
underlying our principal product (formerly known as "Immun-Eeze"), along with
pending international patent applications, and certain other tangible assets and
related trademarks, and copyrights from Gene Pharmaceuticals, LLC, for $150,000
plus royalties tied to future sales which should not be less than a minimum
royalty amount of $3,780,000. In December 2002, the parties agreed to amend the
original agreement to settle the unpaid minimum royalty through issuance of
2,000,000 shares of BioGentec's common stock, plus royalties on future sales of
products. In March 2004, we tentatively agreed to further amend the original
underlying agreement and the terms of the royalty provision in the underlying
agreement, although the specific terms have not yet been finalized. We are
currently negotiating the amendments to the original agreement.

COMMON STOCK. In February 2004, we issued 20,000 shares of restricted common
stock to Ernest Armstrong, our Vice President of Business Development as
additional compensation. The shares were valued at $1.85 per share.

STOCK OPTIONS. In February 2004, we agreed to grant Mr. Ernest Armstrong
1,200,000 options to purchase shares of our s common stock. In addition, St.
Petka Trust, our majority shareholder agreed to transfer 1,000,000 of its
options to purchase shares of our common stock. The exercise prices of these
options were above the market price of our common stock on the date of the
grant; therefore, no expense was recognized.

With regard to any future related party transaction, we plan to fully disclose
any and all related party transactions, including, but not limited to, the
following:

o    disclose such transactions in prospectuses where required;
o    disclose in any and all filings with the Securities and Exchange
     Commission, where required;
o    obtain disinterested directors' consent; and
o    obtain shareholder consent where required.

ITEM 13.  EXHIBITS AND REPORTS ON FORM 8-K
------------------------------------------

(A) EXHIBIT NO.

3.1    Articles of Incorporation*
3.1.1  Certificate of Amendment to Articles of Incorporation*
3.1.2  Certificate of Amendment to Articles of Incorporation**
3.1.3  Certificate of Amendment to Articles of Incorporation***
3.2    Bylaws*
4.1    Convertible Note with Gryphon Master Fund LP
10.1   Asset Purchase Agreement between BioGentec Inc., (fka St. Petka,
       Inc.) and Gene Pharmaceuticals, LLC, (fka Allergy Limited, LLC,)
       as amended
31     Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
       and Chief Financial Officer of the Company
32     Section 906 Certification by Chief Executive Officer and Chief
       Financial Officer * Included in the registration statement on
       Form 10-SB filed on February 8, 2002.
**     Included in Information Statement on Schedule 14C filed June 10,
       2003
***    Included in report on Form 8-K filed July 8, 2004

(b) Reports on Form 8-K

No reports on Form 8-K were filed during the last quarter of the period covered
by this annual report on Form 10-KSB


                                       56
<PAGE>


ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES.
--------------------------------------------------

AUDIT FEES. The aggregate fees billed in each of the fiscal years ended March
31, 2004 and 2003 for professional services rendered by the principal accountant
for the audit of our annual financial statements and review of the financial
statements included in our Form 10-KSB or services that are normally provided by
the accountant in connection with statutory and regulatory filings or
engagements for those fiscal years were $66,050 and $48,000, respectively.

AUDIT-RELATED FEES. There were no fees billed for services reasonably related to
the performance of the audit or review of the financial statements outside of
those fees disclosed above under "Audit Fees" for fiscal years 2004 and 2003

TAX FEES. For the fiscal years ended March 31, 2004 and March 31, 2003, our
principal accountants did not render any services for tax compliance, tax
advice, and tax planning work.

ALL OTHER FEES.  None.

PRE-APPROVAL POLICIES AND PROCEDURES. Prior to engaging its accountants to
perform a particular service, our board of directors obtains an estimate for the
service to be performed. All of the services described above were approved by
the board of directors in accordance with its procedures.



                                       57
<PAGE>


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned in the City of Irvine, California, on July 14, 2004.

Cobalis Corp.,
a Nevada corporation

/s/ Chaslav Radovich
-----------------------------
Chaslav Radovich
principal executive officer, president, treasurer
secretary, director


In accordance with the Exchange Act, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the
dates indicated.


/s/ Chaslav Radovich
-----------------------------                July 14, 2004
Chaslav Radovich
Principal Executive Officer, President, Treasurer
Secretary, Director


/s/ Radul Radovich
-----------------------------                July 14, 2004
Radul Radovich
Director


/s/ Kevin Prendiville
-----------------------------                July 14, 2004
Kevin Prendiville
Director